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BACKGROUND AND AIMS: Adenosine DeAminases acting on 
double-stranded RNA (dsRNA) (ADARs) is a family of enzymes catalyzing 
adenosine to inosine conversion (A-to-I editing) upon binding to dsRNA. 
Inosine is structurally similar to guanosine, and therefore it preferentially base 
pairs with cytosine. That explains why the replication, translation, and splicing 
machineries recognize inosine as guanosine. Hence, A-to-I editing can 
potentially lead to protein recoding (change of amino acid sequence) or 
alternative splicing when it occurs in coding region or at the conserved splicing 
motifs. In hepatocellular carcinoma (HCC), the abnormal A-to-I editing in 
coding regions which result in protein recoding has been shown to contribute 
to cancer development. However A-to-I editing mostly occurs in non-coding 
regions of the genome, and is especially enriched in the 3’ untranslated regions 
(3’UTRs). Additionally, the consequences of extensive 3’UTRs editing remain 
largely unclear. Here, we aim to study the regulatory mechanisms of ADARs 
on the expression of target genes with extensive 3’UTRs editing, and their 
contributions to HCC development. METHODS: Genes with extensive 
3’UTRs editing were selected from our previously published RNA-Sequencing 
(RNA-seq) data generated from primary HCC patient samples. Importantly, 
3’UTRs A-to-I editing sites identified by RNA-seq were further validated by 
Sanger Sequencing. Subsequently, the selected genes with bona fide 3’UTRs 
editing were screened by a luciferase reporter assay to study the functional 
interaction between their 3’UTRs and ADARs. The precise regulatory 
mechanisms of ADARs were deciphered using various ADAR mutants 
(dsRNA binding-, and deamination-depleted mutants). Lastly, the involvement 
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of selected genes in HCC development was studied by various in vitro and in 
vivo assays. RESULTS: Among the identified targets of ADARs, METTL7A 
(Methyltransferase-Like protein 7A) was found to be strongly regulated by 
ADARs. Surprisingly, both the wild type and mutant ADARs could inhibit 
METTL7A expression, indicating an editing-independent regulation by 
ADARs. ADAR editing-independent regulation on METLL7A was 
demonstrated to be mediated through a specific microRNA, miR-27a. The 
expression of miR-27a was shown to be increased by ADARs through their 
interaction with Dicer to promote the processing of pre-miR-27a. Moreover, 
METTL7A was found to be a novel tumor suppressor in HCC, and primary 
HCC tumors demonstrated reduced METTL7A expression. HCC patients with 
lower METTL7A expression have shorter disease-free survival and overall 
survival time. The tumor suppressive functions of METTL7A were further 
confirmed by gain-of-function (overexpression) and loss-of-function 
(knockdown) studies both in vitro and in vivo. CONCLUSIONS: We 
discovered that ADARs can regulate gene expression through an RNA editing-
independent mechanism, mediated by microRNA. Therefore, extensive 
3’UTRs editing for certain genes might be just a footprint of ADAR binding 
with undetectable functional impacts. However through microRNAs 
expression modulation, ADARs can potentially exert profounder effects on 
gene expression beyond just acting as editing enzymes per se. Overall, we 
revealed a microRNA-dependent regulatory mechanism of ADARs 
contributing to HCC, opening another gate to target HCC. 
Keywords: ADARs, 3’UTRs, editing-independent regulation, 
microRNA, METTL7A, HCC  
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1.1 Background  
Hepatocellular carcinoma (HCC) represents the fifth most common type 
of cancer for men and the seventh for women worldwide (Figure 1-1) (Bray et 
al., 2013). The major burden of HCC falls upon developing countries where 
chronic hepatitis B virus (HBV) infection is endemic (Concepts & El-serag, 
2011). Major risk factors for HCC development include chronic infection with 
HBV, hepatitis C virus (HCV), alcoholic and non-alcoholic liver diseases. In 
addition to the increasing incidence rate, HCC also has a high mortality rate of 
0.93, which ranks HCC as the third leading cause of death from cancer 
worldwide (Ferlay et al., 2010). The demoralizing outcome of HCC is mainly 
due to the late manifestation of large tumors, rendering early curative intent 
treatment infeasible. The late symptom onset is the result of a multistep 
transformation process which usually takes 10-30 years. In addition to the 
bleak fact that HCC is asymptomatic in early stage, the available treatment 
options for intermediate-advanced stage patients are also disappointing. The 
extremely low response rate to chemotherapy makes its effects negligible; and 
the only available small molecule inhibitor against multikinases (sorafenib) can 
only prolong the survival of HCC patients for three months (Bruix et al., 2001; 
Concepts & El-serag, 2011). All these facts put more novel and effective 
therapeutic interventions in urgent needs to improve the survival of HCC 
patients, therefore extensive efforts have been devoted to identify new 
druggable molecular targets. Previous studies have focused much attention on 
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revealing DNA mutations and gene expression changes related to HBV and 
HCV infection. However, 30% to 40% of HCC patients are shown not to be 
infected by HBV and HCV, suggesting other driver events could be responsible 
for HCC initiation and progression (Concepts & El-serag, 2011). Recently, 
RNA editing has entered the limelight in cancer research.  
RNA editing is defined as chemical modifications on RNA transcripts 
after synthesis by RNA polymerases. Adenosine to inosine conversion (A-to-I 
RNA editing) is the most prevalent type of RNA editing in human (Nishikura, 
2010). It is a hydrolytic deamination process catalyzed by a family of enzymes 
known as Adenosine DeAminases acting on double-stranded RNA (dsRNA) 
(ADARs) (Goodman et al., 2012) (Figure 1-2). Inosine is structurally similar 
to guanosine, and therefore it preferentially base pairs with cytosine (Figure 
1-3), which explains why the replication, translation, and splicing machineries 
recognize inosine as guanosine. Hence, A-to-I editing can potentially lead to 
protein recoding (change of amino acid sequence) or alternative splicing when 
it occurs in coding region or at the conserved splicing motifs. In hepatocellular 
carcinoma (HCC), abnormal A-to-I editing in coding regions resulting in 
protein recoding has been demonstrated to contribute to cancer development. 
For instance, hyper-editing of antizyme inhibitor 1 (AZIN1) in HCC tumors 
leads to recoding of genetically encoded serine to glycine at position 367 of the 
AZIN1 protein, which leads to a conformational change of AZIN1 and 
increases affinity of AZIN1 to antizyme. Edited AZIN1 therefore sequesters 
antizyme from degrading ornithine decarboxylase (ODC) and cyclin D1 





Figure 1-1 Worldwide incidence and mortality of different cancers in
males and females. Estimated numbers (thousands) of new cancer cases
(incidence) and deaths (mortality) in men (A) and in women (B) in developed 







Figure 1-2 The hydrolytic deamination of adenosine to inosine catalysed 
by Adenosine DeAminases acting on double-stranded RNA (ADARs). 
ADARs catalyse deamination of adenosine to inosine by adding a H2O 
molecule to 6-position. Inosine is structurally similar to guanosine, except for 
a lack of amino group at 2-position. This figure is modified from Goodman et 
al., (2012). 
 
Figure 1-3 Inosine preferentially base pairs with cytidine with Watson-
Crick configuration. Due to the structure similarity between inosine and 
guanosine, editing of adenosine to inosine changes the base pairing property of 
the original nucleotide. Adenosine base pairs with uridine, but inosine base 
pairs with cytidine. Figures adapted from Nishikura, (2010).  
 
Figure 1-4 Involvement of hyper-editing of antizyme inhibitor 1 (AZIN1) 
in hepatocellular carcinoma (HCC). Editing in coding region of AZIN1 leads 
to amino acid change from serine to glycine at position 367. In normal 
hepatocyte AZIN1 fine tunes antizyme activity in degradation of ornithine 
decarboxylase (ODC) and cyclin D1 (CCND1). However during HCC 
development, AZIN1 is increasingly edited, and the edited AZIN1 has higher 
affinity to antizyme, hence neutralizes antizyme from ODC and CCND1 
degradation. Thus edited AZIN1 promotes HCC development. Figures 
modified from Gallo, (2013). 
guanosine 




1.2 Thesis motivation and objectives 
Even though HCC has been reported to have an imbalanced editome in 
both coding and non-coding regions, functional involvement of imbalanced 
editing in HCC development has only been demonstrated with one recurrent 
recoding editing event, AZIN1 (Chan et al., 2013; Chen et al., 2013; Qi et al., 
2014). More importantly, over 90% of A-to-I editing happens in the non-coding 
regions of human genome due to the higher probability of dsRNA secondary 
structure formation between the embedded repetitive elements. Of the non-
coding regions, 3’ untranslated regions (3’UTRs) are where A-to-I editing is 
most significantly enriched (Peng et al., 2012).  
Promiscuous 3’UTRs editing has been associated with different fates of 
the edited mRNAs, including nuclear retention of the target mRNAs by a 
inosine specific nuclear protein complex, nuclease mediated degradations, and 
alteration of microRNA (miRNA) targeting etc. (Borchert et al., 2009; 
Kawahara et al., 2007; Morita et al., 2013; Scadden, 2005; Wang et al., 2013; 
Zhang & Carmichael, 2001). However, recent studies in both C. elegans and 
H. sapiens also indicated that extensive 3’UTRs editing did not alter the 
transcript stability, translatability and subcellular localization (Capshew et al., 
2012; Hundley et al., 2008).  
Given the conflicting findings regarding the functions associated with 
extensive 3’UTRs editing, in conjunction with the fact that there is so far no 
comprehensive study to characterize the 3’UTRs editing in cancers, we decided 
to look into our previously published RNA-sequencing (RNA-seq) data 
generated from primary HCC patient samples from a new perspective. We 
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focused our analysis in 3’UTRs regions to identify the bona fide edited target 
genes. With the selected genes, we aimed to find  
1. Any general trend of 3’UTRs editing in HCC 
2. The impact of extensive 3’UTRs editing on target gene expression 
3. Regulatory mechanisms of ADARs on the expression of the edited 
genes 
4. Functional involvement of the selected genes in HCC development 
1.3 Thesis organization 
This thesis consists of 9 chapters: 
CHAPTER 1 introduces the background knowledge of this thesis, current 
research gaps, and our research motives and objectives. 
CHAPTER 2 presents a literature review relevant to this thesis, including A-
to-I editing, ADARs, editing and cancer development. 
CHAPTER 3 describes the materials and methods applied in the study. 
CHAPTER 4 illustrates how the candidate genes were selected based on RNA-
seq data, validated by Sanger sequencing, and finally screened by luciferase 
assays. 
CHAPTER 5 describes the detailed regulatory mechanism of ADARs to 
suppress METTL7A expression through miRNA modulation. 
CHAPTER 6 presents the functional study of METTL7A in HCC, focusing on 
its expression and 3’UTRs editing status in primary HCC samples, as well as 
its enzymatic activities as a potential methyltransferase. 
CHAPTER 7 lists our alternative hypotheses of this study and other interesting 
candidate genes for future study. 
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CHAPTER 8 discusses our findings in a parallel comparison with the published 
studies.  
CHAPTER 9 concludes the thesis by summarizing the important findings and 
provides future perspectives for studying the functions associated with ADARs 
and A-to-I RNA editing. 




 LITERATURE REVIEW 
2.1 A-to-I RNA editing 
The completion of human genome sequencing project has revealed an 
awkward phenomenon that organism complexity does not correlate with the 
number of protein coding genes (Mattick, 2001). Higher organisms have 
developed different ways to increase their transcriptome and proteome 
diversity to fulfil more complex functions, e.g. post-transcriptional and post-
translational modifications (Baltimore, 2001). An RNA transcript can undergo 
several modifications to generate transcript diversity, e.g. alternative splicing, 
alternative 3’ polyadenylation (Addendum, 2009; Graveley, 2001). RNA 
editing is one of the post-transcriptional processes that can introduce alterations 
to the RNA sequence encoded by the genome. There are different types of RNA 
editing including nucleotide change, deletion or insertion, but A-to-I RNA 
editing is the most prevalent type in animals.  
 
2.1.1 Discovery of A-to-I RNA editing 
RNA editing was originally discovered in trypanosome mitochondria 
where four extra nucleotides not encoded by the gene were found in coxII 
transcript to restore the reading frame of the encoded protein (Benne et al., 
1986). Since then, different types of RNA editing of various RNA molecules 
(e.g. mRNA, tRNA, rRNA, etc) have been documented across multiple species 
(Gott & Emeson, 2000). As one of the most well characterized type of RNA 
editing, A-to-I editing was accidentally discovered as an RNA duplex 
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unwinding activity because scientists failed to apply the antisense RNA 
technique to inhibit gene expression in the fertilized Xenopus embryos. The 
failure of antisense RNA inhibition was found to be due to the failure of stable 
dsRNA formation caused by an intrinsic dsRNA unwinding activity found in 
the fertilized Xenopus embryos (Bass & Weintraub, 1987; Rebagliati & Melton, 
1987). This dsRNA unwinding activity was subsequently proven to catalyse 
the conversion of adenosine to inosine in dsRNA (Wagner et al., 1989). More 
specifically, A-to-I RNA editing was later elucidated as a hydrolytic 
deamination process by using the combined high-performance liquid 
chromatography-mass spectrometry (LC/MS) (Polson et al., 1991). By using 
an RNA duplex with all the adenosines labelled with 13C, and including H218O 
in the unwinding reaction, A-to-I editing was confirmed to be a hydrolytic 
deamination reaction rather than a nucleotide replacement process. H2O 
functioned as an efficient nucleophile during the reaction (Polson et al., 1991). 
 
2.1.2 Substrate and abundance of A-to-I RNA editing  
As suggested by the in vitro A-to-I RNA editing assays with the synthetic 
RNA duplex and recombinant ADARs proteins, dsRNA secondary structure is 
the only necessary structural element for A-to-I RNA editing to happen (Dabiri 
et al., 1996; Scadden & Smith, 2001a; Yang et al., 2006). Therefore A-to-I 
RNA editing can virtually occur at any sequences in the genome which are able 
to form either inter- or intra-molecular dsRNA. However, it seems that inter-
molecular dsRNAs can be more efficiently edited than the intra-molecular 
dsRNAs due to a higher binding affinity of the editing enzymes (Nishikura et 
al., 1991). In addition, a dsRNA of at least 15-20 base pairs (bp) (around two 
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turns of the dsRNA helix) is required for the ADARs proteins to bind in order 
for editing to occur. Lastly, editing efficiency correlates positively with the 
length of dsRNA, with dsRNA longer than 100 bp being edited more efficiently 
compared to the shorter ones. 
The functionally important A-to-I RNA editing events were mostly 
discovered serendipitously in early days, and restricted to brain tissues; 
therefore A-to-I RNA editing was initially regarded as a rare event occurring 
to a limited number of protein recoding genes in the brain (Hartner et al., 2004). 
However many more A-to-I RNA editing sites were anticipated given the 
substantial amount of inosines detected in the rat brain (estimated to be 1 
inosine per 17,000 ribonucleotides) (Paul & Bass, 1998). Recent development 
of high-throughput next-generation RNA sequencing combined with extensive 
bioinformatic analysis has assisted the discovery of A-to-I RNA editing. It has 
been reported that A-to-I RNA editing is a wide spread post-transcriptional 
modification occurring to most of human transcripts (Athanasiadis, Rich, & 
Maas, 2004; Bazak et al., 2014; Levanon et al., 2004; Park et al., 2012; Peng 
et al., 2012). Furthermore, a Rigorously Annotated Database of A-to-I RNA 
editing (RADAR) has recently been established to collect a comprehensive list 
of A-to-I RNA editing sites for H. sapiens, M. musculus, and D. melanogaster 
(available at: http://RNAedit.com). Tissue specific editing level is also 
provided for specific editing sites by the database, giving a hint on editing-
associated biological functions (Ramaswami & Li, 2014). A more general 
database including both A-to-I RNA editing and C-to-U RNA editing (another 
type of less common deamination editing) known as DARNED (Database of 
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Rna Editing in human) is also available for search of a specific gene of interest 
(available at: http://darned.ucc.ie/about/) (Kiran & Baranov, 2010)  
 
2.1.3 The genetic landscape and site selectivity of A-to-I RNA editing 
The distribution of A-to-I RNA editing across the human genome can be 
summarized in Figure 2-1. Even though it only requires dsRNA secondary 
structure for A-to-I RNA editing to happen, A-to-I RNA editing mainly occurs 
in non-coding regions including intronic and untranslated regions (UTRs), 
attributing to the embedded repetitive elements in these regions, such as Short 
Interspersed Elements (SINEs) and Long Interspersed Elements (Levanon et 
al., 2004; Park et al., 2012; Peng et al., 2012). Especially, 3’UTRs are where 
A-to-I RNA editing is most significantly enriched (Peng et al., 2012). 
Moreover, A-to-I RNA editing can also happen to naturally existing dsRNA, 
such as viral RNA genome and the endogenous stem-loop structures formed in 
miRNA and RNA interference (RNAi) pathways. The functional impacts of A-
to-I RNA editing occurred at different locations will be discussed in the next 




Figure 2-1 The landscape of A-to-I RNA editing and its associated 
consequences. A-to-I editing occurred at different genetic regions will have 
different impacts. Recoding editing in exons can change protein amino acid 
sequence, and hence potentially the encoded protein functions. Editing that 
involves splicing motif alteration (creation or elimination) or happens in the 
splicing regulatory elements can affect alternative splicing or splicing 
efficiency. The above two types of editing are site selective. However, 
3’untranslated regions (3’UTRs) tend to have promiscuous hyper-editing due 
to the higher chance of dsRNA formation between the embedded repetitive 
elements, such as Alu. Hyper-editing of 3’UTRs can result in target mRNA 
nuclear retention, degradation by inosine-specific nucleases, or alteration of 
miRNA mediated silencing. Due to the presence of endogenous stem-loop 
structure during miRNA biogenesis pathway, editing can happen at different 
stages along miRNA maturation. Editing occurred outside of miRNA seed 
sequence has been shown to retard efficient Drosha and Dicer processing, while 
editing occurred to the miRNA seed sequence can alter their silencing targets. 
Apart from the endogenous transcriptome, editing can also target exogenous 
dsRNA, such as the virus genome following virus infection, and impose effects 





Site selectivity of A-to-I RNA editing has always been an intriguing 
question in the field. A-to-I editing can be very specific, especially for the 
editing in coding regions, but 3’UTR on the other hand is characterized to have 
nonselective hyper-editing pattern (Nishikura, 2010). The site selectivity of A-
to-I editing is mainly determined by the length and the perfectness of the 
dsRNA substrate. Long and perfect dsRNA (>100 bp) can have up to 50% of 
adenosines being nonselectively edited to inosines. For instance, the 
hypermutations of matrix gene of measles virus during persistent brain 
infection (50% of uridines being detected as cytidines) was proposed due to the 
A-to-I RNA editing of the minus-strand RNA genome (Bass et al., 1989; 
Cattaneo et al., 1988). During the transcription of measles virus, the newly 
transcribed mRNA can potentially base pair with the RNA genome, and 
therefore can serve as a template for extensive A-to-I RNA editing. Such non-
selective promiscuous A-to-I RNA editing also occurs to sense-antisense 
dsRNA paired up by the transcripts of certain genes, such as the Drosophila 4f-
rnp paired with its convergent transcript from the other DNA strand, sas-10, 
and also the dsRNA intermediate formed during trans-splicing of eri-6/7 in C. 
elegans (Fischer et al., 2008; Peters et al., 2003). In contrast, A-to-I RNA 
editing in short dsRNA or long but imperfect dsRNA tends to be site specific, 
which is usually the case of RNA editing in protein coding sequences. The 
specific editing sites are usually found in an imperfect dsRNA structure formed 
by the edited exon sequence folded back to the downstream complementary 
intronic sequence (termed editing-site complementary sequence (ECS)) 
(Nishikura, 2010). Such specific A-to-I RNA editing has been reported for 
different transcripts, e.g. the glutamate receptor B (GluR-B) Q/R site, the 
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GluR-B,-C,-D R/G sites, and the A-E sites of serotonin (5-HT) receptor 2C (5-
HT2CR) (Burns et al., 1997; Higuchi et al., 1993; Lomeli et al., 1994).  
What ultimately determines the site selectivity of A-to-I RNA editing? 
This question still remains largely unresolved; however the dsRNA structure 
and the deaminase domains of ADARs proteins were proposed to play a role 
(Wulff & Nishikura, 2010). For instance, the internal loops of more than 6 
nucleotides within a dsRNA secondary structure delineate the ends of the 
dsRNA duplex to ADARs proteins, therefore restrict ADARs proteins to a 
specific editing site (Lehmann & Bass, 1999). So the bulges and loops present 
in the long and imperfect dsRNA can act as blocks to position ADARs proteins 
to the specific editing sites. In addition, the deaminase domains of ADARs 
proteins also confer editing site selectivity as suggested by the conserved 
editing site preference by the chimeric ADARs proteins (containing the dsRNA 
binding domain of ADAR1 and the deaminase domain of ADAR2 or vice versa) 
in comparison to the original wild type ADARs proteins from which the 
deaminase domains of the chimeric ADARs are from (Wong et al., 2001). 
Lastly, the flanking sequences of the editing site also contribute to the site 
selectivity of ADARs proteins. ADAR1 was shown to have a 5’neighbor 
preference as A = U > C > G, but no apparent 3’ neighbour preference. 
Similarly to ADAR1, ADAR2 also has a 5’ neighbour preference A ≈ U > C = 
G, but additionally it also has a 3’ neighbour preference as U = G > C = A. 
(Lehmann & Bass, 2000; Polson & Bass, 1994). Furthermore, an A:C 
mismatch of the editing site with the complementary RNA strand can 
significantly enhance the editing frequency compared to A:A or A:G 
mismatches or A:U match (Blow et al., 2004; Wong et al., 2001).  
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2.1.4 Decoding of A-to-I RNA editing 
How is A-to-I editing interpreted by different cellular machineries? 
When A-to-I editing was first discovered, it was identified as an RNA duplex 
unwinding activity because of the I:U mismatches (Bass & Weintraub, 1987). 
From the view of base-paring property, A-to-I editing equals to structural 
change, either increasing or decreasing the stability of the targeted dsRNA by 
targeting A:C mismatch or A:U base pair respectively.  
From the view of biological significances, the interpretation of A-to-I 
editing depends on its location (Figure 2-1). Site selective editing in coding 
regions has the potential to recode the protein amino acid sequence because 
inosine is recognized as guanosine by translational machineries, the 
prototypical examples of this category of A-to-I RNA editing are the recoding 
editing of GluR-B and 5-HT2cR (Burns et al., 1997; Sommer et al., 1991). 
Similarly, alternative canonical splicing sites (5’-GU-branch point-AG-3’) can 
also be created or destroyed since splicing machineries also recognize inosine 
as guanosine. One such well known example is the negative autoregulation of 
ADAR2 by self-editing which creates a 3’ proximal splicing acceptor site and 
leads to a frame shift in ADAR2 (Rueter et al., 1999). While editing of the 
canonical splicing motifs is rare, editing of the splicing regulatory elements 
(SREs) in exons is more abundant (Solomon et al., 2013). Instead of creating 
or destroying alternatively spliced isoforms, editing of SREs can affect the 
splicing efficiency.  
For 3’UTRs which consist of the vast majority of editing, understanding 
the role of hyper-editing in this region is still in its infancy, albeit hyper-editing 
of 3’UTRs has been associated with the regulation of transcript stability and 
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subcellular localization. Hyper-editing of 3’UTRs can affect the transcript 
stability through alteration of miRNA targeting sites since inosine 
preferentially base pairs with cytosine. Alternatively, hyper-editing of 3’UTRs 
can recruit inosine-specific nucleases and subsequently lead to the edited target 
degradation. Both human endonuclease V and Tudor staphylococcal nuclease 
have been demonstrated to interact with hyper-edited dsRNAs and promote 
their cleavage (Morita et al., 2013; Scadden, 2005). As for the subcellular 
localization of hyper-edited RNAs, nuclear retention of the edited RNAs has 
been reported by a p54nrb containing tri-protein complex (Zhang & Carmichael, 
2001). However more recent studies suggested that hyper-editing in 3’UTRs 
does not affect the transcript stability, subcellular localization, or translatability 
of the edited RNAs (Hundley et al., 2008). Therefore, the nuclear retention 
mechanism might be a gene-specific phenomenon. Considering the different 
observations from various studies, as well as the enormous transcript diversity 
that can be potentially generated by hyper-editing in 3’UTRs, understanding 
the functions of A-to-I editing in this region still demands intensive efforts.  
Lastly, a class of functionally important small RNAs, miRNAs, is also 
subjected to A-to-I RNA editing due to their intrinsic stem-loop structures 
(Hundley & Bass, 2011). Mature miRNAs are small RNAs of 22 nucleotides 
processed from long primary transcripts (pri-miRNA) containing intracellular 
stem-loop structures (Figure 2-2). Pri-miRNAs usually containing one to six 
miRNA precursors (pre-miRNAs) are first cleaved by Drosha-DGCR8 
complex in the nucleus to pre-miRNAs around 70 nucleotides, and the pre-
miRNAs are exported to cytoplasm by Exportin-5 for further processing by 
another RNase III, Dicer, to form mature miRNAs (Winter et al., 2009). Mature 
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miRNAs regulate gene expression mainly by binding to the 3’UTRs of the 
target genes through partial complementarity. Initial search for A-to-I RNA 
editing of miRNAs focused on a specific miRNA, miR-22, due to its expression 
in a wide range of tissues, and pri-miR-22 was confirmed to have editing at 
multiple adenosines (Luciano et al., 2004). A subsequent systemic study 
suggested that around 16% of human miRNAs are subjected to A-to-I RNA 
editing (Megraw, et al., 2008). The widespread A-to-I RNA editing of pri-
miRNAs was shown to have significant impact on miRNA processing through 
interfering with Drosha and Dicer cleavage as well as on the alteration of 




Figure 2-2 The canonical microRNA biogenesis pathway. Primary 
microRNAs (pri-miRNAs) can be transcribed by RNA polymerase II or III, 
and then are subjected to the cleavage by the microprocessor complex Drosha-
DGCR8 in the nucleus. The resulting precursor microRNAs (pre-miRNAs) are 
then exported to the cytoplasm by Exportin-5-Ran-GTP complex, and further 
cleaved by RNase III Dicer in complex with TRBP (Tar RNA binding protein) 
into mature miRNAs. Lastly, one strand or both strands of the mature miRNAs 
is loaded with Argonaute (Ago2) proteins into the RNA-induced silencing 
complex (RISC) to suppress the target gene expression by target degradation, 
translational repression or deadenylation.  
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2.1.5 Detection of A-to-I RNA editing by RNA-sequencing 
RNA-seq, also known as whole transcriptome shotgun sequencing, takes 
advantage of high-throughput next-generation sequencing technique to reveal 
the whole transcriptome information about mRNA expression and variations 
(Morin et al., 2008; Wang et al., 2009). Comparing to the conventional 
microarray based transcriptomics study, RNA-seq does not rely on the existing 
knowledge of genome sequence. Moreover it has a much larger dynamic range 
for detection of mRNA expression. Most importantly for our study, RNA-seq 
can determine the transcript structure and post-transcriptional modifications to 
a single nucleotide resolution. This means single nucleotide variations (SNVs) 
including mutations and RNA editing can be detected by RNA-seq. 
Specifically for A-to-I RNA editing, because inosine base pairs with cytosine 
during reverse transcription, it will be detected as A-to-G SNVs in RNA-seq 




Figure 2-3 Detection of A-to-I RNA editing by RNA-sequencing. Full length 
RNAs are first fragmented either directly or after conversion to complementary 
DNA (cDNA). A library of cDNA with adaptors is constructed and subjected 
to next-generation sequencing. The resulting sequence reads are either aligned 
to the reference genome or assembled de novo without reference genetic 
sequence to generate transcriptome-scale gene expression and variation map. 
For A-to-I RNA editing, since inosine base pairs with cytidine during cDNA 
generation, A-to-I RNA editing will be detected as A-to-G variation in RNA-




ADARs, the enzymes catalysing A-to-I RNA editing, were originally 
identified as a mysterious RNA duplex unwinding activity in Xenopus laevis 
embryos (Bass & Weintraub, 1987; Rebagliati & Melton, 1987). The discovery 
of RNA duplex unwinding activity was actually propelled by the failed attempt 
to adapt antisense RNA technique to regulate gene expression in Xenopus 
embryos in contrast to the successful application of this technique in Xenopus 
oocytes. The puzzling discrepancy upon injection of the antisense RNAs into 
the Xenopus embryos and oocytes was revealed to be caused by a 
developmentally regulated dsRNA unwinding activity. This dsRNA unwinding 
activity was shown to denature the RNA duplex, and hence rendered the 
antisense RNA inefficient in regulating the expression of the complementary 
genes. Moreover, the RNA duplex unwinding activity was shown to be specific 
to dsRNA, not affected by excess amount of other forms of polynucleotides in 
in vitro assays (Bass & Weintraub, 1987). Later, the RNA duplex unwinding 
activity was confirmed to be a dsRNA specific adenosine deaminase, 
eventually named as ADAR (Bass & Weintraub, 1988; Wagner et al., 1989).  
 
2.2.1 Cloning and evolution of human ADARs 
Human ADAR1 is the first member of the ADARs family of enzymes 
cloned following the biochemical purification and microsequencing of 
mammalian ADAR1 proteins. Mammalian ADAR1 was first purified from 
both bovine liver nuclear extracts and the calf thymus through sequential 
chromatography (Connell & Keller, 1994; Kim et al., 1994). Microsequencing 
22 
 
of the purified proteins yielded peptide amino acid sequence information which 
enabled the generation of a specific probe used for screening of human cDNA 
libraries, and subsequently the first human ADAR1 cDNA was cloned from 
human natural killer cell and HeLa cell cDNA libraries (Keller et al., 1995; 
Kim et al., 1994). Cloning of human ADAR1 cDNA led to the identification 
and cloning of human ADAR2 (also known as RED1) that was discovered to be 
responsible for the specific editing of the Q/R site of GluR-B (Gerber et al., 
1997; Lai et al., 1997; Melcher et al., 1996). Ultimately, a third member 
ADAR3 was identified as a brain specific and editing incompetent protein in 
both rat and human (Chen et al., 2000; Melcher et al., 1996). History of ADARs 
identification and cDNA cloning are summarized in Figure 2-4. 
 
Figure 2-4 Timeline of ADARs discovery and cloning. Refer to the text 
above for the detailed information. 
 
As mentioned above, three ADARs members have been discovered in 
human and rat, and all of them are highly conserved in vertebrates as 
determined by sequence comparative analysis (Slavov et al., 2000a; Slavov et 
al., 2000b). However there is only one ADAR2-like gene, dADAR, in 
Drosophila, but two ADARs genes, CeADR1 and CeADR2 in C. elegans 
(Palladino et al., 2000; Tonkin et al., 2002). When did different organisms 
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acquire ADARs genes during evolution? By searching the genome sequences 
of all eukaryotes, Jin et al. found that ADARs existed in all the multicellular 
animals from sea anemones to human, but absent in yeast and plants; therefore 
they concluded that the first ADAR arose from the split of protozoa and 
metazoan (Jin et al., 2009). Based on the high sequence similarity, they also 
suggested ADAR1 and ADAR2 were the result of gene duplication in early 
metazoan development. However during recent evolution, ADAR1 or ADAR2 
was lost in some species, resulting in only one gene present in certain 
organisms. Lastly, ADAR3 can only be found in vertebrates from fish to human, 
but not in the primitive chordates, and its sequence is closer to ADAR2 
compared to ADAR1. Therefore ADAR3 is most likely acquired recently by 
the vertebrate lineage as a result of gene duplication from ADAR2 (Jin et al., 
2009).  
 
2.2.2 Isoforms, domain structures and the catalytic mechanism of 
ADARs  
As described in the last section, ADARs proteins are highly conserved in 
vertebrates. In human, three members, ADAR1, ADAR2 and ADAR3, have 
been identified (Figure 2-5). However ADAR1 in particular has two major 
isoforms transcribed from alternative promoters, and initiated from different 
start codons due to alternative splicing (George & Samuel, 1999). ADAR1-150 
kDa longer isoform is synthesized from an interferon (IFN) inducible promoter 
and shuttles between nucleus and cytoplasm; in contrast, the truncated 
ADAR1-110 kDa form is transcribed from a constitutively active promoter and 
predominately localizes in the nucleus (Patterson & Samuel, 1995). ADAR1 
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and ADAR2 are editing competent, and ubiquitously expressed in multiple 
human tissues; however no editing activity or substrate has been discovered for 
ADAR3 and its expression is restricted to brain (Chen et al., 2000; Kim et al., 
1994; Melcher et al., 1996). The editing incompetence of ADAR3 can be 
attributed to the fact that homodimerization is critical for ADARs to edit their 
targets, however ADAR3 was shown to exist as monomer in solution. In 
contrast, ADAR1 and ADAR2 can form both homodimer and heterodimer 
(Cho et al., 2003). 
 
Figure 2-5 Human ADARs isoforms and domain structures. There are three 
members of ADARs for human. ADAR1 has two isoforms: ADAR1-150 kDa 
and ADAR1-110 kDa transcribed from different promoters. ADAR1-150 kDa 
is transcribed from an interferon inducible promoter (PI), and ADAR1-110 kDa 
is transcribed from a constitutively active promoter (Pc). The longer ADAR1-
150 kDa form shuttles between the nucleus and cytoplasm by transportin-1 and 
exportin-5, while the rest of ADARs members mainly stay in the nucleus. All 
three members share a common modular domain structure: N-terminus bears 
two to three double stranded RNA binding domains (DRBDs) and C-terminus 
bears the catalytic deaminase domain. In particular, ADAR1-150 kDa carries 
two additional Z-DNA binding domains at its N terminus: Za and Zβ. Likewise, 
ADAR3 has a unique arginine- and lysine-rich domain (R domain) consisting 
of six consecutive arginine residues. ADARs require homodimerization in 
order to edit their targets. Homodimer formation has been shown for ADAR1 




All ADARs share a common modular domain structure, with N-terminal 
two to three repeats of dsRNA binding domain (DRBD) (∼70 amino acids) and 
a C-terminal highly conserved catalytic deaminase domain (Figure 2-5). The 
DRBD forms a conserved α-β-β-β-α configuration and interacts with two 
successive minor grooves across the intervening major groove on one face of 
the dsRNA helix (Ryter & Schultz, 1998). The DRBD makes a direct contact 
with around 16 bp of the dsRNA through a conserved cluster of lysines in a 
KKXXK motif (X is any amino acid), and mutation of the lysines abolishes the 
dsRNA binding ability of ADARs and leads to the concomitant loss of RNA 
editing activity (Ramos et al., 2000; Valente & Nishikura, 2007). 
The C-terminal catalytic domain consists of conserved amino acids 
forming a core deaminase motif. Based on the crystal structure of human 
ADAR2 catalytic domain bound to RNA, two cysteines (C451 and C516) and 
a histidine (H394) are critical to coordinate Zn2+ together with a water molecule 
at the active site (Figure 2-6) (Macbeth et al., 2005). In addition, E396 at the 
active site is also critical for the editing reaction by acting as a proton shuttle 
(Goodman et al., 2012). Mutation of the equivalent residues in human ADAR1 
abolished its editing activity (Lai et al., 1995). One additional interesting 
observation from the crystal structure of ADAR2 catalytic domain is the buried 
inositol hexakisphosphate (IP6) in the reaction core (Figure 2-6), which 
contributes to the protein fold. Given the close proximity of IP6 to the reaction 
centre, it is strongly indicative that IP6 plays a critical role during RNA editing 




Figure 2-6 Residues at ADAR2 active site. The crystal structure of ADAR2 
active site. The Zn2+ is coordinated by C451, C516, H394, and a nucleophilic 
H2O (blue sphere). E396 is another highly conserved residue that acts as a 
proton shuttle, critical for RNA editing reaction. Figure is adapted from 
Macbeth et al., 2005. 
 
In addition to the conserved common domains, different members of 
ADARs also have their unique domains. For instance, ADAR3 has a unique 
arginine rich region domain located at the N-terminus responsible for the 
binding to ssRNA (Chen et al., 2000). However the biological functions 
associated with this domain remain unclear.  
ADAR1-150 kDa has two left-handed Z-DNA binding domains, Zα and 
Zβ, and they function as single bipartite domain. However only Zα domain has 
the specific binding ability to the left-handed Z-DNA conformation (Herbert et 
al., 1997; Schwartz et al., 1999). The crystal structure of ADAR1 Zα domain 
in complex with DNA provided a structural basis for the specificity of Zα to 
the Z-DNA conformation by revealing the contact between Zα and the DNA 
duplex at the ‘zigzag’ sugar-phosphate backbone (Schwartz, 1999). Given the 
specific interaction between Zα and Z-DNA, What could be the associated 
biological significances? One possible role is to recruit the ADAR1-150 kDa 
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isoform to the actively transcribed genes prior to splicing because Z-DNA can 
be formed transiently upstream of the active RNA polymerase due to the 
negative supercoils (Liu & Wang, 1987). In addition to Z-DNA, ADAR1 Zα 
domain also has the ability to bind to Z-RNA conformation, therefore, Zα 
domain might also have a function of recruiting ADAR1-150 kDa isoform to 
Z-conformation prone RNA sequence, e.g. the guanosine and cytosine repeats, 
thereby conferring certain extent of editing site selectivity (Barraud & Allain, 
2012; Brown II et al., 2000; Herbert & Rich, 1999). Lastly, Zα domain not only 
regulates the RNA editing activity of ADAR1, but also affects gene expression 
in vivo (Oh et al., 2002). For instance, the Zα domain was recently found to 
bind to c-Myc promoter G-quadruplex and represses gene expression (Kang et 
al., 2014).  
 
2.2.3 Physiological functions of ADARs in development 
ADARs play important roles during normal development as suggested 
by the different animal models with genetically modified ADARs. In C. elegans, 
homozygous deletion of both CeADR1 and CeADR2 revealed their importance 
in the nervous system as indicated by defective chemotaxis of mutant C. 
elegans (Tonkin et al., 2002). Moreover, the defects in chemotaxis of CeADR1 
and CeADR2 null C.elegans can be rescued by deletion of genes (rde-1 or rde-
4) involved in RNAi pathway, indicating the important functions of ADARs in 
protecting the dsRNA from RNAi-mediated degradation (Tonkin & Bass, 
2003). In Drosophila, deletion of dADAR also mainly affected the nervous 
system and led to severe behavioural defects in adults, like temperature-
sensitive paralysis and locomotor uncoordination. These phenotypes increased 
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with age, and were associated with age-dependent neurodegeneration 
(Palladino et al., 2000). In mouse, homozygous deletion of Adar2 resulted in a 
seizure prone phenotype and early lethality after birth (between P0 and P20) 
due to the increased Ca2+ permeability and subsequently the conductance of α-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor. 
Interestingly this phenotype can be rescued by ectopic expression of the edited 
form of one major Adar2 target, GluR-B, indicating that GluR-B Q/R site is 
physiologically the most important editing target of Adar2 (Higuchi et al., 
2000). Furthermore, mutant mice with Adar2 overexpression driven by human 
cytomegalovirus promoter were also generated, and they demonstrated adult 
onset hyperphagia-related obesity. Of note, the obese phenotype was 
recapitulated in the mutant mice expressing the catalytically inactive Adar2, 
indicating Adar2 may function beyond only as an editing enzyme in vivo (Singh 
et al., 2007). In contrast to the viable phenotype of Adar2-/- mouse, Adar1-/- 
mouse was embryonic lethal (died between E11.5 and E12.5), mainly due to 
the defective haematopoiesis and liver disintegration (Hartner et al., 2004; 
Wang et al., 2000). Recent studies with conditional deletion of Adar1 
confirmed its critical involvement in suppressing the interferon response and 
preventing apoptosis to maintain both adult and fetal hematopoietic stem cells 
(Hartner et al., 2009).  
In addition to the animal models with genetically modified ADARs, 
animals with altered editing pattern of specific substrates were also developed, 
giving insights of the physiological importance of specific A-to-I editing events. 
For instance, GluR-B mRNA is known to be edited from glutamine (Q) to 
arginine (R) at position 586 to nearly 100% in central nervous neurons to 
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control the Ca2+ permeability of AMPA receptors (Sommer et al., 1991). 
Heterozygous mice GluR-B+/ΔECS harbouring one editing incompetent GluR-B 
allele by deleting the ECS demonstrated the expression of unedited GluR-B 
with increased Ca2+ permeability, and eventually developed seizure and died at 
3 weeks of age (Brusa et al., 1995; Higuchi et al., 1993). Another example is 
mice with knock-in of fully unedited or edited 5-HT2CR. 5-HT2CR pre-mRNA 
is subjected to A-to-I editing at 5 sites (A, B, C, D, and E sites) in exon 5, and 
combinatorial editing of the five sites can result in up to 24 different 5-HT2CR 
isoforms with altered G protein-coupling efficiency (Burns et al., 1997; 
Fitzgerald et al., 1999; Wang et al., 2000). A-to-I editing of the 5 sites changes 
the gene-encoded Ile, Asn, and Ile (INI) 5-HT2CR to Val, Gly, and Val (VGV). 
Mice with 5-HT2CR-VGV knock-in displayed severely reduced fat mass even 
in the presence of compensatory hyperphagia, which was caused by the 
constitutive activation of the sympathetic nervous system and increased energy 
expenditure (Kawahara et al., 2008). This reveals the importance of 5-HT2CR 
editing in controlling the metabolism and energy homeostasis, which 
underlines the possible correlation of the editing levels of 5-HT2CR with 
different metabolic rate and obesity observed among individuals of different 
ages and ethnic backgrounds (Kawahara et al., 2008). 
2.3 A-to-I RNA editing and human diseases other than 
cancers 
In human, RNA editing is a tightly regulated process. Disturbance in 
RNA editing has been associated with many diseases, including cancer which 
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will be discussed in the next section (2.4 A-to-I RNA editing and cancer 
development). Significantly different editing site preference of 5-HT2CR was 
observed in the prefrontal cortex of depressed suicidal victims, and failure of 
editing at the Q/R site of GluR-B was suggested to contribute to the neuronal 
death in sporadic amyotrophic lateral sclerosis patients (Gurevich et al., 2002; 
Kawahara et al., 2004). Furthermore loss of function mutations in ADAR1 
were linked to an inherited autosomal dominant disease, dyschromatosis 
symmetrica hereditaria (DSH) (Miyamura et al., 2003). Even though the 
underlying mechanisms of dysregulated editing of specific genes in 
contributing to different diseases remain unclear, the correlation between them 
at least underlies the importance of fine-tuned A-to-I editing to normal cellular 
functions. 
2.4 A-to-I RNA editing and cancer development 
Cancer, like other diseases, has also been associated with the disturbance 
of A-to-I editing. However cancer incidence was not reported to change in 
either ADARs transgenic mouse models or in humans suffering DSH. 
Therefore editing is unlikely an early initiation hit along the transformation 
slope (Hartner et al., 2004; Higuchi et al., 2000; Miyamura et al., 2003; Wang 
et al., 2000). Nonetheless, an editing dysregulation has been associated with 
tumor progression in many different types of cancers. Hence A-to-I RNA 
editing should be considered as a driver event for cancer development. 
However, editing dysregulation cannot be simply categorized as a tumor 
suppressive or oncogenic process, because the ultimate effects of A-to-I editing 
dysregulation depend on the actual edited targets. Furthermore, comprehensive 
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analysis of available editing databases revealed a complex cancer editome 
picture: tumors are characterized by global hypo-editing in the repetitive 
elements accompanied with gene-specific editing pattern along tumor 
transformation, i.e. there is a lack of joint editing trend for different genes in 
cancer (Paz et al., 2007). Therefore, effects of editing disturbance on cancer 
development should be addressed on a gene-specific level. 
 
2.4.1 A-to-I RNA editing and cancer-related persistent virus infection 
Chronic inflammation and cancer development are closely connected, 
and epidemiological evidence suggests that up to 25% of all cancers are related 
to chronic infection or other types of chronic inflammation. Persistent viral 
infection is one of the sources leading to chronic inflammation (Schetter et al., 
2010). ADAR1 has been suggested to be involved in chronic viral infection 
through interactions with both the host and viral genomes (Figure 2-7) 
(Dominissini et al., 2011).  
As an interferon inducible isoform localised in the cytoplasm, ADAR1-
150 kDa isoform constitutes the first-line innate immunity against virus 
infection by directly editing the viruses’ genomes. Editing of HCV RNA 
genome (associated with HCC), human herpes virus 8 Kaposin Transcript 
(associated with Kaposi’s sarcoma and primary effusion lymphoma), and 
Epstein-Barr virus BART6 miRNA (associated with Burkitt lymphoma, 
Hodgkin disease, and nasopharyngeal carcinoma) has been associated with 
reduced virus replication and transforming abilities etc. (Gandy et al., 2007; 
Iizasa et al., 2010; Taylor et al., 2005). In contrast to the antiviral effects on the 
above mentioned viruses, ADAR1 editing activity can sometimes be harnessed 
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by other viruses to facilitate their infection. For instance, 5’-UTR and the Rev 
and Tat coding sequences of human immunodeficiency virus (HIV) are 
subjected to A-to-I RNA editing, and associated with increased viral replication 
and enhanced infectivity (Doria et al., 2009). Hypermutation of the matrix gene 
of measles virus can potentially eliminate the translational initiation codon, 
thus suppresses the expression of matrix protein and helps the virus escape 
from host immune system recognition (Maas & Kawahara, 2006). Therefore 
A-to-I RNA editing should not be simply regarded as a proviral or antiviral 
process during viral infection, given the complex effects observed for different 
viruses.  
To the other side of the host-virus relationship during virus infection, A-
to-I editing also plays critical roles in regulating host immunity. As an essential 
component to constitute all the cells for innate and adaptive immune system, 
hematopoietic stem cells (HSCs) have been shown to require ADAR1 for their 
survival and normal functions (Hartner et al., 2009; XuFeng et al., 2009). HSCs 
with conditional deletion of ADAR1 failed to reconstitute the irradiated 
recipients, developed less differentiated colonies in semisolid methylcellulose 
medium, and experienced increased apoptosis (XuFeng et al., 2009). 
Interestingly, the protection of HSCs from apoptosis by ADAR1 was found to 
be mediated by the global suppression of both type I and type II interferon 
signalling pathways (Hartner et al., 2009). The inhibition of ADAR1 on 
interferon expression was also demonstrated for cells exposed to cytosolic 
DNA. ADAR1 was shown to be a cytosolic DNA sensor, and functioned as a 
negative regulator of the interferon response of cells exposed to cytosolic DNA 
(Wang et al., 2008).  
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Given the multiple conflicting roles of ADARs to both the virus genome 
and host immune system during viral infection, it seems that ADAR1 is the 
critical factor modulating the intimate relationship between the host and virus, 
and contributing to the persistent virus infection for different virus-induced 
cancers. ADAR1 is induced by viral infection due to the interferon response to 
protect the host from virus attack by editing both the virus and host genome; 
however sometimes viruses can hijack ADAR1 editing activity to enhance their 
infectivity. Meanwhile ADAR1 is also involved in protecting the host from 
overactive immune responses by inhibiting the interferon signalling. Therefore 
the negative feedback loop formed by ADAR1 in response to viral infection 




Figure 2-7 ADAR1 is a key determinant for persistent virus infection. In 
response to virus infection, interferon is able to induce the expression of 
ADAR1-150 kDa isoform which contributes to the persistent virus infection by 
multiple actions. ADAR1 can edit virus RNA genome to either enhance or 
inhibit the infectivity. On the other hand, ADAR1 can also edit the host genome, 
especially the cells involved in immune response, e.g. HSCs and T-
lymphocytes to prevent them from apoptosis. In addition, ADAR1 can also 
inhibit dsRNA-activated protein kinase (PKR), and promote virus infection 
independent of editing activity. Last but not least, ADAR1 also suppresses 
interferon expression to protect the host from excessive detrimental immune 
responses.  
 
2.4.2 Altered A-to-I RNA editing in different cancers other than HCC 
Several genes with altered editing frequency in different tumors have 
been identified (Table 2-1). Underediting of GluR-B at the Q/R site in human 
glioblastoma multiforme (GBM) without apparent differential expression of 
ADAR2 was first documented by Mass S. et al (Maas et al., 2001). 
Subsequently, underediting of GluR-B was shown to increase Ca2+ 
permeability of AMPA-type GluR, and in turn facilitated tumor cell migration 
and proliferation (Ishiuchi et al., 2002). Similarly, bladder cancer-associated 
protein (BLCAP) was shown to be underedited in primary bladder cancer, but 
the physiological importance of edited BLCAP remains unexplored (Galeano 








Inhibition of PKR 
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editing of FLNB (filamin B, β) and AZIN1 was identified in Esophageal 
Squamous Cell Carcinoma (ESCC). More importantly, edited AZIN1 
conferred gain-of-function phenotype associated with more aggressive tumor 
behaviours of ESCC (Qin et al., 2014). Lastly, in haematological malignancies, 
abnormal A-to-I editing of hematopoietic cell phosphatase (PTPN6) gene was 
associated with acute myeloid leukemia (AML). The novel editing of PTPN6 
IVS3 putative branch point in AML led to intron3 retention and predicted 
nonsense translation of PTPN6 (Beghini et al., 2000). In short, different cancers 
show distinct editing pattern of relevant genes, and there is an association 
between editing dysregulation and cancer development. However, the 
biological significance of an edited gene on transformation is important to be 




Table 2-1 Altered editing of different genes in different cancers. 
a, glutamate receptor subunit B 
b, a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
c, androgen receptor 
d, component of oligomeric golgi complex 3 
e, signal recognition particle 9 kDa 
f, bladder cancer-associated protein 
g, hematopoietic cell phosphatise 
h, antizyme inhibitor 1 
I, filamin B, β 
j, coatomer protein complex, subunit α 
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2.4.3 A-to-I RNA editome imbalance in HCC 
Even though a few concrete examples have suggested the involvement of 
editing dysregulation in several types of cancers, no aberrant editing has been 
identified in HCC until our group first reported the increased recoding editing 
of AZIN1 (Chen et al., 2013). However HCC cannot be simply regarded as a 
hyper-edited cancer type. More recent large-cohort HCC editome study 
revealed HCC displayed a severely disrupted editome balance characterized by 
gene specific editing pattern (Figure 2-8) (Chan et al., 2013; Qi et al., 2014). 
The newly identified abnormal recoding editing is hyper-editing of FLNB and 
hypo-editing of COPA. Similar to other cancers, there is a lack of joint editing 
trend for different genes in HCC. This is probably caused by the substrate 
specificity of different ADARs members which displayed opposite expression 
changes in HCC (increased ADAR1 and decreased ADAR2) (Figure 2-8). As 
established from both studies, AZIN1 is specifically edited by ADAR1, while 
COPA can only be edited by ADAR2, and FLNB is a common target of 
ADAR1 and ADAR2 (Chan et al., 2013; Chen et al., 2013). Not only did the 
recoding editing showed an opposite editing trend, but also the editing in Alu 
repetitive elements of different genes had the same pattern. Therefore HCC is 




Figure 2-8 Editome imbalance in HCC. HCC displays a severely distorted 
editing profile in both coding and non-coding regions. The imbalanced editing 
profile is characterized by different genes showing opposite editing trend in 
HCC. This can be due to the opposite expression change of ADAR1 and 
ADAR2 (increased ADAR1 expression but decreased ADAR2 expression). 
The substrate specificity of ADAR1 and ADAR2 ultimately leads to the 
opposite editing trend for different genes. Genes showing different editing 
trend are summarized in the table. It is worth pointing out that only AZIN1, 
COPA, and FLNB have been validated as the direct substrates of ADARs. 
AZIN1 is a specific substrate for ADAR1, and COPA is a specific substrate for 
ADAR2, while FLNB can be a common substrate for ADAR1 and ADAR2. 
Other genes in the table still await experimental confirmation for the enzyme-
substrate relationship. 
 
As mentioned earlier, the biological significances of an edited gene on 
transformation are important to be illustrated before claiming the association 
of editing disturbance with cancer development. For HCC, the first evidence 
about involvement of editing in carcinogenesis was established from AZIN1 
recoding editing; however evidences for FLNB and COPA are still lacking. 
Recoding editing of AZIN1 replaces a genetically encoded serine by glycine at 
position 367 of the protein, causing a conformational change of AZIN1 and 
thereby increasing its affinity to antizyme. By doing so, the edited AZIN1 
spares ODC and CCND1 from antizyme mediated degradation, thus it 
promotes HCC cell proliferation (Chen et al., 2013). Given the oncogenic role 
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of edited AZIN1, edited AZIN1 could be a promising drug target for future 
therapeutic development against HCC.  
Similar to the recoding editing, editing in the non-coding regions of 
different genes also shows inconsistent changes in HCC. Editing of miRNAs 
in either normal adult liver tissue or HCC has been reported (e.g. miR-151, 
miR-197 and miR99a). Furthermore, decreased editing of miR-376a and 
increased editing of miR-376c were demonstrated for HCC (Figure 2-8) 
(Mizuguchi et al., 2011). However the study was performed with deep 
sequencing of combined cDNA from 18 patients instead of paired cDNA from 
each individual patient. Therefore, whether there is a joint trend for the editing 
frequency of either miRNA among HCC patients awaits further investigation. 
Specifically for HCC, it is also worth discussing the intricate relationship 
between RNA editing and viral infection, as 60% to 90% of HCC are caused 
by HBV/HCV infection and subsequent chronic inflammation (Hatzaras et al., 
2013). As mentioned in section 2.4.1, it is difficult to categorize editing simply 
as antiviral or proviral mechanism. In support of antiviral functions, IFN 
inducible ADAR1-150 kDa isoform is able to directly edit HCV replicon RNA, 
and inhibit viral replication (Taylor et al., 2005). Furthermore, as an indirect 
antiviral mechanism, ADAR1 is critical for both embryonic and adult 
haematopoiesis, an essential system for maturation of all immune system cells 
(Hartner et al., 2004; Wang et al., 2000; XuFeng et al., 2009). On the other 
hand, ADAR1 has been shown to be able to inhibit the dsRNA-activated 
protein kinase (PKR), an important effecter of antiviral immunity by general 
inhibition of translation initiation, independent of editing activity (Figure 2-7) 
(Nie et al., 2007). Moreover, ADAR1 can also directly edit viral RNA (e.g. 
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HIV), and the editing activity is associated with enhanced virus infectivity 
(Doria et al., 2009). Whether ADAR1 also plays similar proviral roles in HCC 
still awaits further investigation.  
 
2.4.4 Underlying cause of imbalanced editing in human cancer 
How does the editing disturbance occur during cancer development? One 
possible cause is the expression change of editing enzymes, ADARs. As the 
regulatory machineries controlling ADARs activity remain largely unknown, 
most studies have focused on investigating the expression changes of ADARs. 
For instance, both adult and paediatric gliomas were characterized by 
underediting of ADAR2 specific target GluR-B at the Q/R site; however both 
tumors did not show changes of ADAR2 mRNA level. Nonetheless, ADAR2 
activity (as evaluated by the extent of self-editing of ADAR2) was shown to be 
decreased (Maas et al., 2001). To understand this, one should bear in mind that 
ADARs function as homodimers (Cho et al., 2003). Overexpression of one 
ADARs member can affect the editing frequency of the other member’s 
specific target given that non-functional heterodimer between ADARs 
members can be formed, e.g. ADAR1-ADAR2 heterodimer. Indeed both 
ADAR1 and ADAR3 mRNA showed increased expression in brain tumors and 
forced expression of ADAR1 inhibited the editing frequency of ADAR2-
specific sites (Cenci et al., 2008). This might explain the incongruent changes 
between ADAR2 mRNA and its target editing frequency. In other tumors, 
differential expression of ADARs could be more directly responsible for the 
disturbed editing balance of their respective targets. For example, HCC was 
reported to have increased expression of ADAR1 but decreased expression of 
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ADAR2 at both mRNA and protein levels (Chan et al., 2013). The opposite 
expression changes of ADAR1 and ADAR2 were responsible for hyper-editing 
of AZIN1 and hypo-editing of COPA (coatomer protein complex, subunit α) 
respectively. Hence, different tumors seem to have differential expression 
patterns of ADARs. To resolve the dilemma of incongruent expression of 
ADARs across different tumors, an imbalanced ADARs expression model was 
proposed as a general phenomenon observed for cancer (Dominissini et al., 
2011). However, other than ADARs expression, editing can be affected by 
multiple factors including environmental stimuli. Therefore, with more 
research on the regulatory machineries governing ADARs editing activity in 
future, we hope that the underlying causes of editing disturbances in cancer 
could be better understood.   
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 MATERIALS AND METHODS 
3.1 Identification of A-to-I RNA editing by RNA-seq 
Since we used our previously published RNA-seq data for this thesis, this 
part of materials and methods is adapted from the published work by Chen et 
al. (Chen et al., 2013). 
 
3.1.1 RNA extraction and Illumina mRNA library preparation 
Primary tumor and matched adjacent non-tumorous (NT) tissues of 3 
HCC patients (Case No. 448, 473 and 510) in GZ cohort were selected for 
RNA-Seq. Among 3 patients, two of them (448 and 473) are positive for liver 
cirrhosis. All 3 patients are HBV-positive and HCV-negative. Total RNA was 
isolated using the mirVanaTM miRNA isolation kit (Ambion, Austin, TX, USA), 
and was then treated with the DNA-free kit (Ambion) for the removal of 
genomic DNA. PolyA+ RNA was purified using Dynabeads mRNA 
purification kit (Invitrogen, Carlsbad, CA) following the manufacturer’s 
instructions. Approximately 100 ng of mRNA was fragmented by incubation 
for 5 min at 94°C in 5 X Array Fragmentation Buffer (Ambion). Double 
stranded cDNA was synthesized using the SuperScript Double-Stranded cDNA 
Synthesis kit (Invitrogen) with random hexamer, and purified using a QiaQuick 
PCR column (Qiagen, Valencia, CA). The resulting double-stranded cDNA 
fragments were then repaired using the DNA Terminator End Repair Kit 
(Lucigen, Middleton, WI) and purified using a QiaQuick PCR column. The 
Klenow 3’ to 5’ exo-polymerase (NEB, Ipswich, MA) was used to add a single 
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‘A’ base to the 3’end of blunt phosphorylated DNA fragments. Following 
purification, the Illumina PE Adapter (Illumina,San Diego, CA) was ligated to 
the end of the DNA fragments using the Quick Ligation™ Kit (NEB, Ipswich, 
MA). DNA fragments ranging from approximately 280 to 300 bp were excised 
from a 2% low-melting agarose gel. The fragments were amplified by 10 
thermocycles using AccuPrime™ Pfx DNA Polymerase (Invitrogen). The PCR 
product was separated on a Novex 8% TBE polyacrylamide gel (Invitrogen) 
and stained with SYBR Gold (Invitrogen). Gel slice containing the 340- to 360-
bp fragments were excised and purified using the QiaQuick Gel Extraction Kit 
(Qiagen). The concentration of the gel-purified DNA fragments was measured 
using a ND-1000 UV/Vis spectrophotometer (NanoDrop Technologies, 
Wilmington, DE). 
 
3.1.2 Solexa sequencing and read mapping 
Cluster generation and sequencing were conducted using the Standard 
Cluster Generation kit v4, and 36-Cycle Sequencing kit v3 on the Illumina 
Cluster Station and GAIIx following the manufacturer’s instructions. cDNA 
libraries from the three paired HCC tumors and the corresponding NT 
counterparts (HCC448N/T, HCC473N/T, and HCC510N/T) were sequenced 
with 58-base single-reads. Raw data from the GAIIx were analysed using the 
Illumina Real Time Analysis (RTA) v1.6 software. A phi-X 174 control lane 
was included in each Solexa run for matrix, phasing, and error rate estimations 
as recommended by the manufacturer. The error rate of the Phi-X control error 
rate was < 0.28% for all of the sequencing runs.  
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Ribosomal RNA sequences were first removed from GA reads by 
aligning them to 28S (NCBI RefSeq accession NR_003287.2), 18S (NCBI 
RefSeq accession NR_003286.2), human ribosomal DNA complete repeating 
unit (HSU13369) and mitochondrial ribosomal RNA (Ensemble transcript ID 
ENST00000387347 and ENST00000389680) using Bowtie with default 
parameters (Langmead et al., 2009). The high-quality reads were then aligned 
against the human genome assembly (NCBI Build 37.1/hg19) using TopHat 
v1.0.14 with the RefSeq refGene annotation (Trapnell et al., 2009), which was 
downloaded from the UCSC Genome Browser (Zweig et al., 2008). 
Additionally, alignment was also performed using Burrows-Wheeler Aligner 
v0.5.8c (BWA) and CLC Genomics Workbench v4.6 (CLC bio, Denmark) to 
detect Single Nucleotide Variations (SNVs) (Li & Durbin, 2009). Finally, 
mapping results were processed with custom scripts and visualized on the 
UCSC Genome Browser as a custom track. 
 
3.1.3 Transcript assembly and abundance estimation using cufflinks 
Expression estimation and tests for differential expression were 
conducted using the Cufflinks program v0.8.3 (Trapnell et al., 2010). Cufflinks 
uses the normalized RNA-Seq fragment counts to measure the relative 
transcript abundances. The unit of measurement is fragments per kilobase of 
exon per million fragments mapped (FPKM). 
 
3.1.4 Variant Discovery 
Briefly, aligned files from the three different aligners (see above) were 
processed with SAMtools and, subsequently, with VarScan (v2.2) for SNVs 
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detection (Koboldt et al., 2009). Variance calling was constrained to genetic 
locations with at least 10X coverage, a variation frequency of greater than 30% 
and a base quality of more than 15. By subtracting the variations between the 
tumor and matched NT samples, somatic SNVs were obtained and compared 
with NCBI dbSNP Build 131. Finally, we intersected the somatic SNVs 
detected from the three aligners to derive a set of high-confidence SNVs. 
3.2 Clinical samples 
HCC patient tumor and matched adjacent non-tumorous specimens used 
for DNA, RNA and protein extraction were obtained from Sun Yat-Sen 
University Cancer Centre (Guangzhou, China), as well as their associated 
clinicopathological summaries, between 2002 and 2007. Samples were 
surgically removed and snap-frozen in liquid nitrogen. Written informed 
consents for the use of the collected clinical specimens for medical research 
were obtained from all the patients. All the samples used in this study were 
approved by the committees for ethical review for research involving human 
subjects at Sun Yat-Sen University and National University of Singapore.  
3.3 Mice 
Mice used in this study were 4- to 5-week old nonobese diabetic mice 
with severe combined immunodeficiency (NOD/SCID). All mice were kept on 
a standard chow diet and had free access to food and water. All experiments 
were approved by Institutional Animal Care and Use Committee of National 
University of Singapore. 
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3.4 Cell lines 
SNU-398, HuH-7, SMMC-7721, NIH/3T3, and HEK-293 cell lines were 
purchased from the American Type Culture Collection. SNU-398 was cultured 
in Roswell Park Memorial Institute medium (RPMI) supplemented with 10% 
fetal bovine serum (FBS). HuH-7, SMMC-7721, NIH/3T3, and HEK-293 cells 
were maintained in Dulbecco’s Modified Eagle’s medium (DMEM) 
supplemented with 10% FBS. All cells were incubated in humidified 
incubators containing 5% CO2 at 37°C. 
3.5 Construction of plasmids used in this study 
3.5.1 pmirGLO Dual-Luciferase miRNA Target Expression Vector 
The pmirGLO Dual-Luciferase miRNA target expression vector was 
purchased from Promega (USA) (Figure 3-1). This vector is designed to study 
the regulation of miRNAs on target gene expression by either introducing 
either putative miRNA target sites or the 3’UTRs sequences of target genes 
downstream of the firefly luciferase open reading frame (luc2). Luc2 is the 
main reporter driven by human phosphoglycerate kinase promoter to reflect the 
expression change of mRNA, and renilla luciferase (hRluc-neo) serves as a 
control reporter to normalize the transfection variations. For the purpose of our 
study, we cloned full length 3’UTRs of selected genes to the multiple cloning 
site downstream of Luc2 to assess the effects of 3’UTRs A-to-I editing on gene 
expression. Primer sequences used for cloning are listed in Table 3-1. 
Specifically for METTL7A 3’UTR, in order to test the specific targeting effects 
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of miR-27a and miR-27b, the miR-27a/b targeting site was mutated by 
overlapping PCR using primers listed in Table 3-1.  
 
Figure 3-1 pmirGLO Dual-Luciferase miRNA target expression vector. 
Full length 3’UTRs of selected genes were cloned to the multiple cloning site 
(MCS) downstream of firefly luciferase (Luc2). Luc2 is driven by human 
phosphoglycerate kinase (PGK) promoter, and acts as the main reporter to 
indicate the expression of mRNA. Renilla luciferase (hRluc-neo) serves as a 
control reporter to normalize the transfection variations. Available restriction 
enzyme recognition sites for cloning are listed under the plasmid map. Figure is 
adapted from https://www.promega.sg/products/reporter-assays-and-transfecti
on/reporter-vectors-and-cell-lines/pmirglo-dual-luciferase-mirna-target-





Table 3-1 Sequences of primers used for cloning the full length 3’UTR of selected genes. Restriction enzyme sites incorporated 
into the primers were highlighted in red. 
 





enzyme sites on 
vector 
CCNYL1-3’UTR-cF CCTTGAGCTCAAGGAGAAATGAGGGGTTATAAC SacI SacI 
CCNYL1-3’UTR-cR AATTGCTAGCTTAATTAAAATAGAGTTTATTAGCTTTTAA NheI NheI 
TNFAIP8L1-3’UTR-




T NheI NheI 
MDM2-3’UTR-cF CCTTACTAGTTTGACCTGTCTATAAGAGAATTATA SpeI NheI 
MDM2-3’UTR-cR CCTTCTCGAGTGCTTGCTTTACGGTTTTATTTTGC XhoI XhoI 
METTL7A-3’UTR-cF CCTTGAGCTCTGTGAGCTGGCAGTTAAGAGCTG SacI SacI 
METTL7A-3’UTR-cR AATTGCTAGCTAAACCATATTTCTGTTCCTAAC NheI NheI 
MTDH-3’UTR-cF CCTTGAGCTCAATTTTTTTTCCTGAATTGGACATG SacI SacI 








ATAGTTGCAAAGAAC   
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3.5.2 pLenti6-ADAR lentiviral expression vector 
Wild type ADAR1-110 kDa coding sequence was subcloned from open 
reading frame (ORF) cDNA clone purchased from GeneCopoeiaTM (Product ID: 
C0744, USA) (Figure 3-2A). BamHI and XhoI restriction enzymes were used 
to clone the coding sequence to pLenti6 lentiviral expression vector (Figure 
3-2B). Wild type ADAR2 coding sequence was cloned from cDNA prepared 
from HCC cell line HuH-7. All the ADARs mutants used in this study were 
generated by PCR based mutagenesis (Lai et al., 1995). Primers used to generate 
the point mutations are listed in Table 3-2. 
 
Figure 3-2 Maps of ADAR1 ORF cDNA clone from GeneCopoeia and the 
pLenti6 vector. (A) Map of ADAR1 ORF cDNA clone from Gene Copoeia. 
(B) Map of pLenti6 lentiviral expression vector used in our study. Figures 
adapted from http://www.genecopoeia.com/product/search/detail.php?prt=1&
cid=&key=C0744 and http://www.lifetechnologies.com/order/catalog/product






Table 3-2 Sequences of primers used to clone wild type and mutant 
ADARs into pLenti6 lentiviral expression vector. Red letters indicate the 
restriction enzyme recognition sites introduced without changing the encoded 
amino acids. Restriction enzyme recognition sites introduced to the middle of 
genes are underlined. Blue color highlights the introduction of amino acid 
mutations. A1 stands for ADAR1-p110, and A2 stands for ADAR2. 
Primer 
name 
Primer sequence Incorporated 
restriction 






























































































3.5.3 pMIRNA1 lenti-miR expression vector 
miRNA precursors were amplified from human placenta genomic DNA 
to obtain a fragment containing 500 bp both upstream and downstream of the 
mature miRNA sequence, and then cloned into the pMIRNA1 lenti-miR 
expression vector (Figure 3-3). However for miR-27a/b, only the 
corresponding pre-miRNA coding sequences were cloned because miR-27a/b 
genes localize in close proximity to other miRNAs belonging to the same 
cluster. pMIRNA1 lenti-miR expression vector is a kind gift from CSI 
colleague Dr. Yan Junli, which was originally purchased from System 
Biosciences (USA). Primers used for cloning miRNA precursors are listed in 
Table 3-3. 
 
Figure 3-3 Map of pMIRNA1. A fragment of around 1000 bp encoding 
miRNA precursor sequence is inserted downstream of CMV promoter between 
EcoRI and NotI restriction enzyme sites. One unique feature of the vector is 
the presence of copGFP (copepod green fluorescent protein) fluorescent 
marker driven by the Human elongation factor-1 α (EF1α) promoter, therefore 
the expression of GFP (green fluorescent protein) will indicate the expression 
of miRNA precursors. This vector is a HIV based vector, and therefore can be 
used for lentiviral mediated miRNA expression. Figure is adapted from 






Table 3-3 Sequences of primers used for cloning miRNA precursors. Red 
letters indicate the EcoRI and NotI restriction enzyme recognition sites 
introduced for cloning. However there is no need to introduce EcoRI site into 
hsa-miR-654 F primer because an intrinsic EcoRI site exits in the 1000 bp PCR 
fragment. For the scrambled control, mature miR-93 seed sequence is 
scrambled, as shown by the blue colour highlighted letters. 
Primer name Primer sequence 
hsa-miR-93 F TTAAGAATTCACTACATCACAGCAGCATACGTG 
hsa-miR-93 R TTAAGCGGCCGCGTGCCTAAGGGGAAGGTAGG 
hsa-miR-93 scr F AGTGTGATTACCCAACCTGTACTATTGATCCAGACCC
CAGAGCCCCCGGGACACGTTCT 
hsa-miR-93 scr R ACAGGTTGGGTAATCACACTGTTACTCATTGACCAGAC
CGCGAGCCCCCAGGACTGAGGTC 
hsa-miR-612 F TTAAGAATTCTCTGCTGCTGCAGTAAGTAAGTG 
hsa-miR-612 R TTAAGCGGCCGCCTTCCATTCTCTGATCTGTCAGC 
hsa-miR-17 F TTAACAATTGGTATTTGCTAAGTGGAAGCCAGA 
hsa-miR-17 R TTAAGCGGCCGCAATAGCAGGCCACCATCAGT 
hsa-miR-940 F TTAAGAATTCCATGTCTGAGGAGTGGGTATCAT 
hsa-miR-940 R TTAAGCGGCCGCACTGCAGTCACTTAGGCTGCTC 
hsa-miR-20b F TTAAGAATTCCAGTGCAGGTAGCTTTTTGAGAT 
hsa-miR-20b R TTAAGCGGCCGCCCTGCGGTTTACAGATGGAT 
hsa-miR-654 F CACCATCAGGGAAGAGACAATAA 
hsa-miR-654 R TTAAGCGGCCGCACCCCGTTCATTCAGATACG 
hsa-miR-93 F TTAAGAATTCACTACATCACAGCAGCATACGTG 
hsa-miR-93 R TTAAGCGGCCGCGTGCCTAAGGGGAAGGTAGG 
hsa-miR-610 F TTAAGAATTCAATTGGAGTCCCAGAAGTAGAGG 
hsa-miR-610 R TTAAGCGGCCGCGACAGAGTTTCACCATGTTAGCC 
hsa-miR-637 F TTAAGAATTCTAAAGTGCCAGAGGTGGTTAGAC 








3.5.4 pLKO.1-puro vector for short-hairpin RNA (shRNA) expression 
pLKO.1-puro vector is a third generation lentiviral backbone for cloning 
and expression of shRNAs to knockdown specific target genes (Figure 3-4). It 
was provided kindly by CSI colleague Dr. Ding Lingwen, which was originally 
purchased from Sigma-Aldrich® (USA). shRNAs against ADAR1 and 
METTL7A were designed following instructions of the RNA consortium 
(http://www.broadinstitute.org/rnai/public/). Selected shRNA sequences are 
listed in Table 3-4. shRNAs were cloned into PLKO.1-puro vector following 
Addgene’s PLKO.1 protocol (http://www.addgene.org/tools/protocols/plko/). 
For ADAR2, Validated shRNA vectors were directly purchased from Sigma-
Aldrich® (TRCN0000050939 and TRCN0000050942). 
 
Figure 3-4 Map of PLKO.1-puro vector for shRNA cloning. Sense and 
antisense oligos are annealed and ligated to PLKO.1-puro vector digested by 
AgeI and EcoRI restriction enzymes. The insertion of XhoI site in the oligos 
allows quick verification for the successful insertion of shRNAs to the vector 
by restriction enzyme digestion. This vector carries a puromycin resistant gene, 
allowing for selection of stably knockdown cells. Figure is adapted from 
http://www.sigmaaldrich.com/life-science/functional-genomics-and-rnai/shrn
a/library-information/vector-map.html#pLKO visited on 17th Oct 2014. 
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Table 3-4 Sequences of primers used to construct shRNAs against ADAR1 
and METTL7A. Sequences of the commercially available shRNAs against 
ADAR2 are also included. 

























































3.6 Lentivirus production, titration and transduction 
3.6.1 Lentivirus packaging 
Lentivirus production for different lentiviral expression vectors follows 
the protocol described below. Packaging of the virus was done with HEK-293 
cells which should be maintained in the medium free of antibiotics at optimal 
density. HEK-293 cells are very easy to detach from plates, should be handled 
with extreme caution during culture and virus packaging. 
Day 1. Seed 3.8 million of HEK-293 cells to 10-cm cell culture plate in 
10 ml of antibiotic-free growth medium.  
Day 2. 24 hours later, the cells should reach 70%~80% of confluence 
before transfection. Transfect the cells with the following plasmid mixtures 
using Lipofectamine® 2000 transfection reagent following the manufacturer’s 
instructions. Incubate the cells overnight till the next morning. 
pCMV-dR8.91 (packaging plasmid) 5 µg 
VSV-G (envelop plasmid) 0.5 µg 
PLKO.1-puro or pLenti6 vectors 5 µg 
 
Day 3.Carefully change the medium to 9 ml of antibiotic-free growth 
medium. 
Day 4. 24 hours after incubation, virus containing medium was harvested 
and transferred to polypropylene storage tubes. Add another 9 ml of antibiotic-
free growth medium back to the cells. 
Day 5. Repeat virus harvesting as last step. Virus containing medium was 
then pooled for downstream filtration using 0.45 µm Millex-HV Syringe Filter 
Units (Merk Millipore, USA) to remove any packaging cells. Virus were then 
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aliquot and frozen at -80°C. Minimize the number of freeze/thaw cycles in 
order to maintain the virus titres. 
3.6.2 Lentivirus titre determination 
Lentivirus titres were determined using mouse fibroblasts NIH/3T3 cells 
in 12-well plate. 
Day 1. Seed 3X105 of 3T3 cells to each well of a 12-well plate, incubate 
the cells at 37°C, in a humidified CO2 incubator.  
Day 2. Prepare 5 tubes of 10-fold serial dilutions of virus soup from the 
stock using normal growth medium (DMEM +10% FBS), as depicted in 
Figure 3-5. Pipette 100 µl of virus to each well containing 900 µl of growth 
medium. Transduction was done in the presence of hexadimethrine bromide 
(Sigma-Aldrich, USA) at a final concentration of 8 µg/ml.  
Day 3 -2 weeks. Change the virus containing medium with fresh growth 
medium supplemented with appropriate selection antibiotics, and keep the 
selection pressure for 2 weeks until visible plaques appear. Plaques were 
stained with crystal violet and counted under light microscopy. Calculate the 
virus titre as number of PFUs per 1 ml of virus stock. PFU stands for the plaque 




Figure 3-5 Flow chart of virus titre determination. A serial 10-fold dilutions 
were made from the virus stock, and 100 µl of the diluted virus soup was added 
to each well of 12-well plate containing 900 µl of growth medium 
supplemented with hexadimethrine bromide (final concentration 8 µg/ml). 
 
150 µl 
15 µl 15 µl 15 µl 15 µl 15 µl 
135 µl 135 µl 135 µl 135 µl 135 µl 
900 µl 





3.6.3 Lentiviral transduction 
Day 1. Seed appropriate number of cells so that they can reach 60%~70% 
confluence next day. 
Day 2. Add the virus soup to the cell at MOI of 8 with hexadimethrine 
bromide at a final concentration of 8 µg/ml. MOI stands for multiplicity of 
infection, calculated as PFU/cell. Spin the cells with virus containing medium 
at 2,400 rpm for 90 minutes at 32ºC.  
Day 3. Change the virus containing medium to fresh growth medium.  
Day 4. Start to select the successfully transduced cells by the appropriate 
antibiotics.  
3.7 Luciferase reporter assays 
Luciferase assay was performed with the Dual-Glo® Luciferase Assay 
System (Promega, USA) 48 hours post transfection in 96-well plate (Corning 
USA) following the manufacturer’s instructions. Briefly, same volume of 
Dual-Glo® Luciferase Reagent to the culture medium was added to each well. 
With at least 10 minutes of incubation, firefly luminescence was measured. 
Maximum intensity of the luminescence can be measured within 2 hours of 
addition of Dual-Glo® Luciferase Reagent before the signal starts to decay. To 
measure the renilla luciferase activity, a volume of Dual-Glo® Stop & Glo® 
Reagent equal to the original culture medium volume was added. Similarly, the 
luminescence signal was measured at least 10 minutes later by Infinite 200 
PRO microplate reader (TECAN, Switzerland). Detailed experiments 
involving different vectors are described in the following two sections.  
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3.7.1 Co-transfection of pmirGLO Dual-Luciferase expression vector 
with pLenti6-ADARs overexpressing vector 
To screen the selected target genes whose 3’UTRs can be potentially 
regulated by A-to-I RNA editing, pmirGLO-3’UTRs vectors were co-
transfected with pLenti6-ADARs wild type overexpressing vectors in HEK-
293 and SNU-398 cells at a mass ratio of 1:3 by Lipofectamine® 2000 
transfection reagent (Life Technologies, USA) following the manufacturer’s 
instructions. 48 hours post transfection, luciferase activity was measured as 
described above.  
With selection of METTL7A for further mechanistic study, we further 
confirmed METTL7A as a direct downstream target of ADARs by performing 
a dose dependent luciferase assay in HEK-293 cells. Briefly, for each well of 
the 96-well plate, 20ng of pmirGLO-METTL7A-3’UTR and increasing amount 
of plenti6-ADARs overexpressing vectors at mass ratios of 1:0.2, 1:0.4, 1:0.8, 
1:1.6, and 1:3.2 were used for co-transfection. 48 hours post transfection, 
luciferase activity was measured as described above. 
3.7.2 Co-transfection of pmirGLO-METTL7A-3’UTR with pMIRNA1 
lenti-miR expression vector 
To screen miRNAs for potential targeting of METTL7A 3’UTR, 
pmirGLO-METTL7A-3’UTR was co-transfected with different pMIRNA1 
lenti-miR expression vectors at a mass ratio of 1:9 in HEK-293 cells. 48 hours 
post transfection, luciferase activity was measured as described above. 
pmirGLO-STMN1-3’UTR and miR-101 were included as a positive control for 
this assay, and they are kindly provided by Dr.Yan Junli from CSI Singapore. 
Similarly, to confirm the targeting of miR-27a/b against METTL7A 3’UTR, a 
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dose dependent assay was performed with mass ratio of pMIRNA1-miR-27a/b 
to pmirGLO-METTL7A-3’UTR ranging from 1:2.5, 1:0.8, and 1:0.5. 
3.8 RNA preparation, reverse transcription and real-time 
PCR 
Total RNA was prepared with the RNeasy mini kit (QIAGEN, Germany) 
except those used for miRNA expression analysis. For miRNA expression 
analysis, total RNA from HuH-7 cells 72 hours post-transfection were prepared 
using mirVana™ miRNA Isolation Kit (Life Technologies, USA). The RNA 
concentration was measured by NanoDrop (Thermo Scientific, USA).   
Reverse transcription was performed with SuperScript® III Reverse 
Transcriptase (Life Technologies, USA) following the manufacturer’s 
instructions. Briefly 1 μg of total RNA mixed with 1 μl of Oligo(dT)20 (50 μM) 
and 1 μl of dNTP (10 mM) was heated at 65ºC for 5 minutes, then placed on 
ice for at least 1 minute to denature any secondary structure. Add the following 
reverse transcription (RT) mixture including: 4 μl of 5X RT buffer, 2 μl of 
0.1M dithiothreitol (DTT), 1 μl of RNaseOUTTM (40 U/μl), and 1 μl of 
SuperScriptTM III RT (200 U/μl) to the reaction, and incubate at 50°C for 50 
minutes. Stop the reaction by heating at 85°C for 5 minutes. 
Quantitative real-time PCR (qPCR) (except for miRNA expression 
analysis) was performed with GoTaq® qPCR Master Mix (Promega, USA) 
using a Rotor-Gene 6000 (Qiagen, Germany). Briefly, take the amount of 
cDNA equivalent to 20 ng of starting RNA for each qPCR reaction. Mix the 
cDNA with the following components to a final of 15 µl of reaction volume: 
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7.5 µl of 2X GoTaq® qPCR Master Mix, 0.3 µl of qPCR forward and reverse 
primers (stock concentration: 10 µM). Perform the qPCR reaction with the 
following protocol: 95°C for 5 minutes (denaturation), 40 cycles of 95°C for 
15 seconds and 60°C for 60 seconds (annealing and extension), and 1 cycle of 
60-95°C (dissociation).  
For miRNA expression analysis, 10 ng of total RNA with 0.5 ul of 
synthetic RNA spike-in (5X107 copies) were reverse transcribed with 
miRCURY LNA™ Universal RT microRNA PCR reagents (Exiqon, 
Denmark). cDNA was diluted 20 times, and the quantification of miRNAs was 
performed with ExiLENT SYBR® Green Master Mix Kit (Exiqon, Denmark) 
following the manufacturer’s instructions. Individual miRNA LNA™ PCR 
primer sets were purchased from Exiqon. 
3.9 RNA immunoprecipitation (RIP) 
RIP was performed following the protocol provided by Abcam, which can 
be found at http://www.abcam.com/epigenetics/rna-immunoprecipitation-rip-
protocol. For our purpose of studying the interaction between ADARs and 
METTL7A mRNA, RIP was performed in two cell lines HEK-293 cells and 
SMMC-7721 cells after overexpression of ADARs. HEK-293 cells were 
transiently transfected with ADARs overexpression constructs for 48 hours 
before RIP being performed, while SMMC-7721 cells were transduced with 
lentiviral vectors to constitutively express ADARs. 
Briefly, cells with overexpression of ADARs were harvested by scraping 
after washing twice with 1X phosphate-buffered saline (PBS), and then 
resuspended in 2 ml of 1X PBS. 2 ml of nuclear isolation buffer (Table 3-5) 
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and 6 ml of H2O were then added to the cell suspension, and cells were 
incubated on ice for 20 min with frequent mixing. Nuclei were harvested by 
spinning the cells at 2,500 g for 15 min at 4°C, and then resuspended in 1 ml of 
RIP buffer (Table 3-5). Chromatin was sheared using a dunce homogenizer 
with 20 strokes. Nuclear debris was then removed by centrifugation at 13,000 
rpm for 10 min at 4°C. 100 µl of the lysate was frozen down for downstream 
RNA extraction, which was used as the input control. The rest 900 µl of total 
lysate was split into two fractions for downstream immunoprecipitation. One 
fraction was used for IgG control. The other fraction was used for 
immunoprecipitation with 4 µg of anti-ADAR1 (ab88574) or anti-ADAR2 
antibody (SAB1405426-50UG). With the addition of either IgG or the antibody 
of interest, cell nuclear lysate was gently rotated for overnight at 4ºC. Next day, 
40 µl of proteinA/G Dynabeads (Life Technologies, USA) were added into the 
mixture and incubated for 1 hour at 4ºC with gentle rotation. The beads were 
then washed for three times, and each time with 1 ml of RIP buffer for 5 min at 
4ºC with gentle rotation. Lastly, the beads were washed once with 1 X PBS, 
before being resuspended with 1 ml of TRIzol (Life Technologies, USA) for 
future RNA extraction.  
Table 3-5 Buffer recipes for RNA immunoprecipitation. 
Nuclear isolation buffer RIP buffer 
1.28 M sucrose 150 mM KCl 
40 mM Tris-HCl pH 7.5 25 mM Tris pH 7.4 
20 mM MgCl2 5 mM EDTA 
4% Triton X-100 0.5 mM DTT 
 0.5% NP40 
 100 U/ml RNAase inhibitor (RNasin® 
Ribonuclease Inhibitor, Promega) (add fresh 
each time) 
 Protease inhibitors (cOmplete, EDTA-free, 
Roche) (add fresh each time) 
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3.10 Measurement of METTL7A 3’UTR A-to-I RNA editing 
by Sanger sequencing 
The first Alu element of METTL7A 3’UTR containing multiple editing 
sites was amplified to evaluate the average editing frequency of METT7A 
3’UTR. PCR was performed with cDNA generated as described above. The 
PCR product was purified by QIAquick PCR purification kit (Qiagen, 
Germany), and sent for Sanger Sequencing by 1st BASE (Singapore) using the 
forward primer. PCR primer sequence is shown below (Table 3-6). Percentage 
of editing was estimated based on the ratio of peak area under G to A.  
Table 3-6 Sequences of primers used to perform PCR of METTL7A 3’UTR. 
Primer name Primer sequence Annealing 
temperature 
METTL7A-F5 GGGAAGAAAGAGTTTTGCTCTTG 60 °C 
METTL7A-R5 TGGGAGACAATAGAAAATGGCTA 60 °C 
3.11 Protein harvest and western blot 
Cells were either scraped in cold 1X PBS directly, or trypsinized and 
washed with cold 1X PBS before being lysed with the following lysis buffer (3 
times the packed cell volume): 50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1 mM 
EDTA, 1% NP-40, and 10% glycerol supplemented with complete protease 
inhibitor cocktail (Roche, Switzerland). Cell lysates were incubated on ice for 
30 minutes for sufficient lysis, and were then spin down to remove the cell 
debris.  
Protein concentration was determined by Bradford protein assay (Bio-
Rad, USA) following the manufacturer’s instructions. Briefly, protein 
standards were prepared with 5 dilutions of bovine serum albumin (BSA). Mix 
1, 3, 5, 7, and 9 µl of BSA (1 mg/ml) with 1 ml of 1X Dye Reagent, and 
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incubate the reaction at room temperature for at least 5 minutes before 
measuring the absorbance at 595 nm. Protein concentration was determined in 
the similar way by mixing 1 µl of the cell lysate with 1 ml of 1X Dye Reagent.  
For western blot analysis, 30~60 µg of the cell lysates were denatured in 
1X SDS-PAGE sample loading buffer (buffer component: 50 mM Tris-HCl pH 
6.8, 2% SDS, 10% glycerol, 1% β-mercaptoethanol, 12.5 mM EDTA, and 0.02 % 
bromophenol blue) by heating at 100 ºC for 5 minutes. Proteins were separated 
by SDS-PAGE minigel (6% gel for ADAR1 and ADAR2, 12% gel for 
METTL7A) until the blue front reached the bottom of the gel. Final 
concentration of the 1X gel electrophoresis buffer is: 28.8 g of glycine, 6.04 g 
of Tris base, 2 g of SDS, and 2 L of ddH2O. Proteins were then transferred to 
Immun-Blot® PVDF membrane 0.2 µm pore size (Bio-Rad, USA) using wet 
transfer at 4ºC (95 V for 2 hours). 1X Transfer buffer consists of 28.8 g of 
glycine, 6.04 g of Tris-HCl, 400 ml of methanol and 1.6 L of ddH2O. PVDF 
membrane was then stained with Ponceau S (Sigma-Aldrich, USA) to check if 
the proteins were transferred to the PVDF membrane successfully. Afterwards 
the membrane was blocked with 5% (v/v) skim milk (50 mM Tris.HCl, pH 7.4, 
150 mM NaCl, 0.1% Tween 20) (Nacalai Tesque, USA) for 1 hour at room 
temperature, and incubated with primary antibodies with agitation overnight at 
4ºC. The antibodies were diluted in 5% skim milk blocking buffer (Table 3-7). 
Next day, the blot was washed with 1X washing buffer (50 mM Tris.HCl, pH 
7.4, 150 mM NaCl, 0.1% Tween 20) with agitation for 3 times, 10 minutes for 
each time, and then incubated with horseradish peroxidase (HRP) conjugated 
secondary antibodies diluted in 5% skim milk blocking buffer for 1 hour at 
room temperature. Finally the blot was developed using Luminata Crescendo 
65 
 
Western HRP substrate (Merk Millipore, USA). Alternatively, if the 
chemiluminescence signal is too weak, SuperSignal West Femto 
Chemiluminescent Substrate (Thermo Scientific, USA) was used. The films 
were exposed using X-Ray film processor SRX-101A (KONICA MINOLTA, 
Japan). Band intensity was estimated using ImageJ software (http://imagej.nih.
gov/ij/).  
Table 3-7 Antibodies used for western blot. 
Antigen Cat. No. Supplier Dilution 
ADAR1 ab88574 abcam 1:1000 
ADAR2 SAB1405426-50UG Sigma-Aldrich 1:1000 
METTL7A sc-130168 Santa Cruz 1:50 
a-Tubulin sc-32293 Santa Cruz 1:5000 
GFP sc-9996 Santa Cruz 1:1000 
goat anti-mouse IgG-HRP sc-2005 Santa Cruz 1:5000 
goat anti-rabbit IgG-HRP sc-2004 Santa Cruz 1:5000 
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3.12 Cell viability assay 
Number of viable cells was assessed by a colorimetric assay using 2,3-
bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) 
(Roche, Switzerland) following the manufacturer’s instructions. The assay is 
based on the cleavage of XTT by alive cells to form an orange formazan dye, 
which can be accurately quantified by a spectrophotometer detector. Briefly, 
1000 cells were seeded to each well of a 96-well plate in 100 µl of growth 
medium one day before the assay. Next day, 51 µl XTT labelling mixture 
containing 1 µl of XTT labelling reagent and 50 µl of electron coupling reagent 
was added to each well. With 4-24 hours’ incubation at 37ºC, absorbance was 
measured by a microplate reader (TECAN, Switzerland) at wavelength of 490 
nm against the absorbance at the reference wavelength of 650 nm.  
3.13 Cell cycle analysis by flow cytometry 
Cell cycle analysis was performed based on the measurement of DNA 
content using propidium iodide (PI) (Life Technologies, USA) staining of the 
cells. PI binds to DNA by intercalating between bases with little or no sequence 
specificity, and it binds to DNA with a stoichiometry of one dye per 4-5 base 
pairs of DNA (retrieved from Life Technologies https://www.lifetechnologies.
com/order/catalog/product/P3566). However PI can also bind to RNA, 
necessitating the RNase treatment for DNA staining (Suzuki et al., 1997). Once 
bound to the nucleic acids, the fluorescence of PI is enhanced 20~30 fold, with 
the excitation maximum at 535 nm and the emission maximum at 617 nm. For 
detection, PI fluorescence is generally detected in the FL-2 channel of flow 
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cytometers if the cells are stained with PI alone, and detected in FL-3 channel 
if the cells are stained with an FITC- or a PE-conjugated antibody. 
Cells were fixed with 70% of ethanol on ice for 15 min, and collected by 
centrifugation at 1,500 rpm for 5 min. Fixed cells were then stained with 500 µl 
of PI-solution in 1X PBS (50 μg/ml of PI, 0.1 mg/ml RNase A, and 0.05% Triton 
X-100) for 40 min at 37ºC, harvested by centrifugation at 1,500 rpm for 5 min, 
and washed with 1 ml of 1X PBS twice. Lastly, cells were resuspended in 1 ml 
of 1X PBS for flow cytometric analysis (BD™ LSR II).  
3.14 In vitro focus formation and soft agar colony formation 
assays 
In vitro focus formation assay was performed to assess the transforming 
ability of cells to grow without contact inhibition by seeding them at a very low 
density. Transformed cells are able to form dense and raised foci on a confluent 
monolayer of cells, which can be visualized by staining with crystal violet. 
Briefly, 1000, 2000, and 3000 stably transduced cells were seeded in 6-well 
plate in the presence of selection antibiotics, and cultured for 1 to 2 weeks. The 
formed foci were stained with 0.5% (m/v) crystal violet (Sigma-Aldrich, USA) 
prepared in 25% (v/v) methanol for 10 minutes, and then washed with water 
until the background staining on the plate was clear. Colonies with more than 
50 cells were counted by light microscopy.  
Soft agar colony formation assay was performed to monitor the 
anchorage-independent growth of transformed cells, which is considered as the 
most stringent and accurate in vitro assay to assess the transforming ability of 
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cells. Briefly, 5X103 of stably transduced cells were seeded in 0.4% of 
SeaPlaqueTM agarose (Lonza, Switzerland) on top of a solidified layer of 0.6% 
of agarose in a 6-well plate. 3 weeks later, colonies with more than 50 cells 
were counted by light microscopy. To prepare the bottom layer of 0.6% of 
agarose, mix one volume of 2X growth medium (2X DMEM or RPMI 
supplemented with 20% of FBS) with one volume of 1.2% stock agarose 
dissolved in ddH2O. 1.2% stock agarose solution should be equilibrated to 37ºC 
in a water bath to prevent it from solidifying. Wait for the bottom layer of 0.6% 
agarose to solidify before putting the top layer of 0.4% agarose containing the 
cells. Similarly, to prepare the top layer of 0.4% agarose. Mix one volume of 
1X growth medium containing desirable number of cells, one volume of 2X 
growth medium, and one volume of 1.2% stock agarose solution. Wait until the 
0.4% agarose solidifies before putting the plate into humidified tissue culture 
incubator, 37°C, 5% CO2 atmosphere.  
3.15 Cell invasion assay 
Cell invasion properties and the associated metastatic potential were 
assessed with BD BioCoat Matrigel Invasion Chambers. The chambers consist 
of Falcon Cell Culture Inserts which contains 8 micron pore size PET membrane 
covered with a thin layer of Matrigel Basement Membrane Matrix at the bottom. 
The Matrigel occludes the 8 micron pore, and prevents the non-invasive cells 
from migrating through the PET membrane. On the other hand, the invasive 
cells are able to migrate through the PEZ membrane which can be easily 
detached and stained for light microscopy. 
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Before seeding the cells for the invasion assay, the Matrigel coated 
invasion chambers (24-well configuration) were first rehydrated with 500 µl of 
warm (37ºC) DMEM medium without FBS added to both the inserts and the 
wells for 2 hours in a humidified tissue culture incubator, 37°C, 5% CO2 
atmosphere. After rehydration, the medium was carefully removed without 
disturbing the coated Matrigel matrix on the membrane. Cells were prepared in 
DMEM medium without FBS at a density of 5x104 cells/ml. Chemoattractant 
which is the DMEM medium supplemented with 10% of FBS in our study, was 
added to the wells of BD Falcon TC Companion Plate (750 µl for the 24-well 
configuration). 25,000 cells in 500 µl of DEME were seeded into the chambers 
and incubated for 22 hours in a humidified tissue culture incubator, at 37ºC, 5% 
CO2 atmosphere. After incubation, the non-invading cells remained on the top 
of the membrane were removed by scrubbing with cotton tipped swabs. Cells 
that have invaded through the Matrigel matrix were stained with 0.5% (m/v) 
crystal violet (Sigma-Aldrich, USA) prepared in 25% (v/v) methanol for 10 
minutes, and then washed with water until the background staining was clear. 
Allow the inserts to air dry before counting the invaded cells under the light 
microscopy.  
3.16 In vivo subcutaneous injection 
Subcutaneous injections were performed as described before (Yong et al., 
2013) Briefly, 3x106 of SNU-398 control (empty vector transduced) and 
METTL7A overexpressing cells were mixed with 1 volume of Matrigel, and a 
total of 200 ul of cell and Matrigel mixture was injected subcutaneously into 
the left and right flanks of a 4- to 5-week old male NOD/SCID mice. Tumor 
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formation was monitored for three weeks, and tumor volume was calculated 
based on the formula: Volume = 0.5 × width2 × length. Similar experiments 
were also performed for HuH-7 cells with stable METTL7A knockdown. 
3.17 Statistical analysis 
Data were expressed as mean ± SEM from at least three independent 
experiments. Data analysis was performed with GraphPad Prism 5 and SPSS 
statistical package for Windows (V.16; SPSS). Comparison between two 
groups was done with unpaired two tailed Student’s t test, except for the 
comparison of METTL7A mRNA in HCC tumors to their adjacent non-
tumorous specimens where the Mann-Whitney U test was used. Comparison 
among more than two groups was performed with one- or two-way analysis of 
variance adjusted with the Bonferroni post test. Survival of HCC patients 
categorized based on the tumor METTL7A expression level was analysed by 
Kaplan-Meier plot and log rank tests. P value < 0.05 was considered as 
statistically significant. (*P < 0.05; **P < 0.01; ***P < 0.001)  
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 SELECTION OF METTL7A AS AN 
ADARs EDITING TARGET IN HCC 
Hepatocellular carcinoma (HCC) is the most common type of liver 
malignancy, and accounts for approximately 700,000 cancer associated deaths 
per year (Ferlay et al., 2010). Among the genetic and epigenetic aberrances 
described in HCC, both overexpression of ADAR1 and downregulation of 
ADAR2 occur in more than 50% of patients (Chan et al., 2013), rendering an 
imbalanced editome in both coding and non-coding regions, including hyper-
editing of AZIN1 and FLNB, and hypo-editing of COPA  (Chan et al., 2013; 
Chen et al., 2013). More importantly, the contributions of imbalanced editing 
to HCC development have been demonstrated with a recurrent RNA editing 
event in the coding region of AZIN1 (Chen et al., 2013). However effects of 
ADARs on expression of genes with extensive 3’UTRs editing and the 
underlying mechanisms remain to be illustrated. Therefore, in this study, we 
focused on 3’UTR regions where A-to-I editing is enriched. Genes with 
extensive 3’UTRs editing were selected based on the RNA-seq data generated 
from three pairs of primary HCC tumors and their matched adjacent non-
tumorous or normal (NT) specimens (Chan et al., 2013).  
4.1 Global A-to-I RNA editing site identification by RNA-seq 
of primary HCC samples 
To identify the global transcriptome variations in HCC, total poly(A)+ 
RNA from 3 pairs of primary HCC tumor and matched NT tissues 
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(HCC448N/T, HCC473N/T and HCC510N/T) were subjected to high-
throughput RNA-seq. Detailed analysis of the RNA-seq data has been 
described before (Chan et al., 2013). Briefly, to identify A-to-I RNA editing 
sites, SNVs were called using VarScan by comparing the RNA-seq data to the 
reference human genome (NCBI Build 37.1/hg19), and filtered against NCBI 
dbSNP database (Build 135) to eliminate the germline variations (Koboldt et 
al., 2009). To further restrain the false positive rate of calling the potential A-
to-I editing sties, the resulted SNVs were further cleared by removing sites with 
either more than two types of variations identified or with 100% variation 
frequency.  
First, we profiled all 12 possible RNA SNVs in our dataset. Our dataset 
showed a significant enrichment of A-to-G and T-to-C type of variations 
(Figure 4-1). Potential A-to-I RNA editing will be detected as A-to-G variation 
for genes on the positive strand, and conversely it will be detected as T-to-C 
variation for genes on the negative strand. Therefore the enrichment of A-to-G 
and T-to-C type of SNVs in our HCC RNA-seq dataset confirmed the previous 
report describing A-to-I RNA editing as the most abundant type of RNA editing 
in human (Levanon et al., 2004; Nishikura, 2010). Next, we combined the A-
to-G and T-to-C type of variation into a list of potential A-to-I RNA editing 
sites, and mapped them to different regions across the whole genome. We 
found that more than 90% of potential A-to-I RNA editing occurred in the non-
coding regions including introns, intergenic regions, and UTRs (Figure 4-2). 
However the uneven distribution of potential A-to-I RNA editing sites across 
different genetic elements might be due to the intrinsic difference in the 
sequence length of different genetic elements, for instance the low percentage 
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of potential A-to-I RNA editing in coding sequence (CDS) might be simply 
due to the fact that 98% of human genome is non-coding regions (Elgar & 
Vavouri, 2008). Hence we calculated the number of potential A-to-I RNA 
editing sites per megabase (Mbp) for different genetic regions. With this 
normalization, A-to-I RNA editing was found to be most significantly enriched 
in 3’UTRs regions (Figure 4-3), consistent to the previous publication (Peng 
et al., 2012). The observed enrichment of A-to-I RNA editing in 3’UTRs could 
be due to the high abundance of SINEs in 3’UTRs leading to higher chance of 
dsRNA secondary structure formation which is necessary for A-to-I RNA 
editing to occur. 
 
Figure 4-1 Different types of RNA SNVs identified by RNA-seq in HCC. 
Consistent to the previous report, our HCC RNA-seq also revealed the 
significant enrichment of A-to-G and T-to-C type of variations for human 
transcriptome. Potential A-to-I RNA editing will be detected as A-to-G 
variation for genes on the positive strand, and as T-to-C variation for genes on 
the negative strand. Therefore our HCC RNA-seq also confirmed that A-to-I 















Figure 4-2 Majority of A-to-I RNA editing happens in the non-coding 
regions. Potential A-to-I RNA editing sites are combined from the list of A-to-
G and T-to-C variations. Around 90% of potential A-to-I RNA editing occurs 
in the non-coding regions. CDS, coding sequence; UTR, untranslated regions. 
 
 
Figure 4-3 Significant enrichment of potential A-to-I RNA editing in 
3’UTR regions. To normalize the length difference between different genetic 
regions, number of SNVs (potential A-to-I RNA editing sites) per megabase 
was calculated. 3’UTR was shown to be significantly enriched for potential A-

























































4.2 Imbalanced A-to-I RNA editing of 3’UTRs in HCC 
HCC has been reported to display an editome imbalance, characterized 
by different editing patterns for different genes, e.g. hyper-editing of AZIN1 
and FLNB, and hypo-editing of COPA (Chan et al., 2013). Since A-to-I RNA 
editing is significantly enriched in 3’UTRs regions, we were interested to study 
if editing imbalance also occurred in this region. Therefore we focused our 
subsequent bioinformatic analysis specifically on 3’UTRs.  
First, we categorized A-to-I RNA editing sites of 3’UTRs for each patient 
sample (patient ID: 448, 473 and 510) into three groups: NT specific (N), 
common to NT and HCC (N & T), and HCC specific (T). We then intersected 
the editing sites among the three patient samples for each category to obtain the 
high-confidence ones (Oliveros, 2007) (Figure 4-4). High-confidence editing 
sites were defined as those present in at least two out of the three patient samples. 
Interestingly, we observed a distinct 3’UTRs editing profile in HCC tumors 
compared to the matched adjacent NT tissues with only around 22% of editing 
sites overlapped between them (Figure 4-5). The distinct 3’UTRs editing 
profile in HCC suggests the possible involvement of aberrant 3’UTRs editing 
in HCC development. Therefore it would be interesting to identify some 





Figure 4-4 Intersection of the potential 3’UTRs A-to-I RNA editing sites 
between HCC patient samples. Potential 3’UTRs A-to-I RNA editing sites 
were categorized into normal specific (N), tumor specific (T) and shared by 
normal and tumor samples (N&T) for each patient sample. Editing sites of each 
category were intersected among the three patient samples to select the high-




Figure 4-5 HCC displayed an imbalanced editing profile in 3’UTRs. High-
confidence A-to-I RNA editing sites were defined by the presence in at least 2 
out of 3 patient samples. HCC tumors only shared around 22% of the overall A-




4.3 Validation and selection of candidate genes with extensive 
3’UTRs A-to-I RNA editing 
To validate the reliability of our dataset in identifying the bona fide A-
to-I RNA editing sites, we randomly chose 23 sites for validation by Sanger 
sequencing the PCR products of both genomic DNA and cDNA. Bona fide A-
to-I RNA editing would be detected as A-to-G mutation in cDNA comparing 
to the genomic DNA. By Sanger sequencing, 20 out of 23 sites were confirmed 
to be bona fide A-to-I RNA editing sites, indicating that 87% of the editing 
sites reported in our 3’UTRs dataset are reliable. Two representative genes with 
the validated 3’UTRs editing were shown (Figure 4-6). In addition to the 
editing sites identified by RNA-seq, we also discovered additional 46 novel 
editing sites during Sanger sequencing validation. This indicates that 
identification of A-to-I RNA editing by RNA-seq is limited by the sequencing 
depth and Sanger sequencing is more sensitive in identifying A-to-I RNA 
editing. Lastly, we also observed the promiscuous editing patterns of 3’UTRs, 
and 5 out of 31 genes (CCNYL1, TNFAIP8L1, MDM2, METTL7A, and MTDH) 
with multiple A-to-I RNA editing sites in their 3’UTRs and potential 
involvement in cancer development were selected for further study (Table 4-1). 
Those genes were selected based on 2 criteria: first, there are multiple A-to-I 
RNA editing sites in their 3UTRs; second, these genes should carry functions 




Figure 4-6 Validation of A-to-I RNA editing by Sanger sequencing. 
Validation was performed with Sanger sequencing of the PCR products from 
both genomic DNA (gDNA) and cDNA. A-to-I RNA editing is detected as A-
to-G mutation in cDNA compared to gDNA. The gDNA shown here was from 
HCC tumor sample to rule out the possibility of somatic mutation. (A) 





Table 4-1 Candidate genes selected based on the RNA-seq of primary HCC patient samples 
Gene ID 3’UTR length No. of editing 
sites a 
Found in N or T Functions 
CCNYL1 2,474 bp 3 Tumor specific Cyclin-Y-Like Protein 1, its paralog 
gene CCNY is highly similar to cyclin 
B3, and able to activate c-Myc 
transcriptional activities (Li et al., 2009) 
TNFAIP8L1 3,138 bp 2 Common  Tumor necrosis factor-alpha-induced 
protein-8 like-1, also known as TIPE1, 
highly expressed in human carcinoma 
cell lines, especially viral DNA 
transformed cell line (Cui et al., 2011)  
MDM2 5,583 bp 5 Common Negative regulator of p53 which is a 
critical tumor suppressor, and mutated 
(or inactive) in most human cancers 
(Wade et al., 2013) 
METTL7A 2,367 bp 13 Common  Also known as AAM-B, targeted to 
lipid droplet, predicted to be a 
methyltransferase based on sequence 
homology (Zehmer et al., 2008a)  
MTDH 5,590 bp 4 Tumor specific Also known as AEG-1 or LYRIC, 
amplified and overexpressed in HCC. 
High expression of MTDH correlates 
with tumor aggressiveness (Sarkar, 
2013)  
a Number of editing sites present in at least two out of three patients in RNA-seq data 
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Extensive 3’UTRs editing of the target genes could only suggest a strong 
physical interaction between the promiscuously edited 3’UTRs and ADARs. 
To investigate if there is any functional interaction between ADARs and the 
edited 3’UTRs, a luciferase reporter assay was conducted using luciferase-
3’UTRs constructs (Luc-3’UTRs) which contain full-length 3’UTRs of the 
selected genes inserted downstream of firefly luciferase open reading frame 
(ORF) in the pmirGLO Dual-Luciferase expression vector (Figure 4-7A). 
Hence changes in the luciferase activity upon ADARs overexpression suggest 
potential functional regulations of the corresponding 3’UTRs by ADARs. 
Genetic structures of the selected 5 genes (CCNYL1, TNFAIP8L1, MDM2, 
METTL7A, and MTDH) are illustrated in Figure 4-7B. Luc-3’UTRs constructs 
were co-transfected with either ADAR1-p110 or ADAR2 overexpressing 
vectors into HEK-293 cells. Overexpression of ADAR2 decreased the 
luciferase activity of the Luc-3’UTRs constructs for all the selected genes, 
except MTDH (Figure 4-8A). Moreover, METTL7A-3’UTR also demonstrated 
decreased luciferase activity upon ADAR1 overexpression (Figure 4-8A). The 
successful overexpression of ADAR1 and ADAR2 was confirmed by qPCR 
(Figure 4-8B). More importantly, we also measured the 3’UTRs editing 
frequencies of the selected genes upon overexpression of ADARs. Surprisingly, 
only METTL7A 3’UTR showed a good negative correlation between the 
luciferase activity and the 3’UTR RNA editing level (Figure 4-8C). In contrast, 
the 3’UTRs of CCNYL1 and TNFAIP8L1 did not demonstrate any significant 
increase in the RNA editing frequencies even though their luciferase activities 
did decrease at least when ADAR2 was overexpressed (Figure 4-8C). The 
discrepancy between the luciferase activity and the 3’UTRs RNA editing 
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frequency indicated that ADARs might play some editing independent roles in 
regulating the expression of certain genes, e.g. CCNYL1 and TNFAIP8L1. 
Given the better correlation of METTL7A 3’UTR RNA editing frequency and 
its luciferase activity, we decided to focus on METTL7A to study the regulatory 




Figure 4-7 Luciferase reporter construct and the genetic diagrams of 
selected genes. (A) The schematic diagram of pmirGLO Dual-Luciferase 
expression vector. The full length 3’UTRs of selected genes (Table 4-1) were 
cloned into the multiple cloning site (MCS). (B) The genetic structures of 
selected genes. Black boxes represent the coding sequence (CDS); empty boxes 
stand for the short interspersed elements (SINEs); and lines indicate the 
untranslated regions (UTRs). + and – signs indicate the strand specificity (sense 







Figure 4-8 Luciferase reporter assay to screen the ADARs regulated genes. 
(A) Luciferase activity of pmirGLO-3’UTRs for the indicated genes 48 hours 
post co-transfection with ADARs overexpressing constructs into HEK-293 
cells. RLU, relative luminescence unit. EV, empty vector. (n = 4; **P < 0.01; 
***P < 0.001). (B) The relative expression of ADARs in (A) was confirmed 
by qPCR. (n = 4; ***P < 0.001). (C) Representative chromatograms of 
CCNYL1, METTL7A, and TNFAIP8L1 3’UTRs in response to ADARs 
overexpression. cDNA of HEK-293 cells co-transfected with Luc-3’UTRs and 
ADARs overexpressing constructs was used for PCR and Sanger sequencing. 





4.4 METTL7A as a bona fide target of ADARs 
DsRNA is the necessary secondary structure for ADARs to bind and thus 
A-to-I editing to occur. To demonstrate that METTL7A 3’UTR is targeted by 
ADARs, the sequence of METTL7A 3’UTR was subjected to RNA secondary 
structure prediction by CentroidFold (Sato et al., 2009). As expected, the first 
Alu element encoded by the negative DNA strand and the third Alu element 
encoded by the positive DNA strand were predicted to form an extensive 
dsRNA secondary structure with high confidence, spanning around 300bp 
(Figure 4-9). The two Alu elements are from the same family, AluSq2, and are 
predicted to form an extensive dsRNA secondary structure due to the sequence 
similarity. To further confirm the regulation of METTL7A-3’UTR by both 
ADAR1 and ADAR2, the luciferase assay was refined by using an increasing 
amount of ADAR1 and ADAR2 for transfection in HEK-293 cells. With 
increasing expression of both ADAR1 and ADAR2, a dose-dependent 
reduction of the luciferase activity of pmirGLO-METTL7A-3’UTR was 
observed (Figure 4-10A and B). Additionally, the reduction of the luciferase 
activity correlated negatively with the increase in the average editing frequency 
of METTL7A 3’UTR. The average editing frequency of METTL7A 3’UTR was 
calculated from 10 representative editing sites selected based on our previous 
RNA-Seq data and DARNED (DAtabase of RNa Editing) public database 
(Figure 4-11A and B) (Kiran & Baranov, 2010). A chromatogram of one 
representative editing site within METTL7A 3’UTR in response to ADARs 
overexpression is illustrated in Figure 4-11C. In the chromatogram, with 
increasing expression of ADARs from top to bottom, there is a gradual increase 
of the area under G peak compared to the area under A peak for the indicated 
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editing site. This indicates a dose-dependent induction of METTL7A-3’UTR 
RNA editing by ADARs. More importantly, RNA immunoprecipitation (RIP) 
with anti-ADAR1 and anti-ADAR2 antibodies in both HEK-293 cells and 
SMMC-7721 cells confirmed that there was a strong physical interaction 
between ADARs and METTL7A mRNA (Figure 4-12). 
 
Figure 4-9 METTL7A 3’UTR RNA secondary structure. The first Alu 
element (on the negative strand) and the third Alu element (on the positive strand) 
of METTL7A 3’UTR were predicted to form an extensive double stranded RNA 
secondary structure by CentroidFold. Shown is the heat color gradation from 
blue to red indicating the base-pairing possibility from 0 to 1. The amplified 




Figure 4-10 Dose-dependent regulation of METTL7A 3’UTR by ADARs. 
(A) Luciferase activity (mean ± SEM) of pmirGLO-METTL7A-3’UTR 
measured 48 hours post co-transfection with the indicated amounts of ADARs 
constructs in HEK-293 cells. EV, empty vector. RLU, relative luminescence 
unit. (n = 3; **P < 0.01; ***P < 0.001). (B) Relative expression of ADARs 







Figure 4-11 RNA editing of METTL7A 3’UTR with increasing amounts of 
ADARs used for co-transfection. (A) Sequence showing the PCR amplicon 
targeting METTL7A 3’UTR for detection of A-to-I RNA editing. Forward and 
reverse primer sequences are highlighted in yellow, as well as the 10 
representative editing sites. (B) The average editing frequency (mean ± SEM) 
of METTL7A 3’UTR calculated from the 10 representative editing sites based 
on the mixed chromatograms of Sanger sequencing. (n = 3; *P < 0.05). (C) 
Chromatogram of one representative editing site of METTL7A 3’UTR from (B) 
with increasing amounts of ADARs from the top to the bottom. Values indicate 







Figure 4-12 RNA immunoprecipitation (RIP) of ADARs in HEK-293 and 
SMMC-7721 cells. (A) Immunoblost showing the successful overexpression of 
ADAR1 and ADAR2, as well as the successful immunoprecipitation of them in 
HEK-293 cells. EV, empty vector. IP, immunoprecipitate. (B)-(C) qPCR of the 
indicated genes with RNA immunoprecipitated by anti-ADAR1 and anti-
ADAR2 antibodies in HEK-293 cells (B) and SMMC-7721 cells (C). METTL7A 
mRNA was shown to be significantly enriched in ADARs RIP samples 
compared to IgG control, as well as to other endogenous control genes (β-actin, 







SUPPRESSION OF ADARS ON METTL7A  
 
We have shown that ADARs could suppress the luciferase activity of 
pmirGLO-METTL7A-3’UTR in a dose-dependent manner. Moreover, RIP of 
both ADAR1 and ADAR2 also demonstrated the direct interaction between 
ADARs and METTL7A mRNA. However the initial luciferase reporter assay 
used to screen the candidate genes suggested that ADARs have editing-
independent functions. Therefore we decided to study if ADARs regulate 
METTL7A expression in an editing dependent or independent manner. 
5.1 Generation of deaminase domain and dsRNA binding 
domain mutants of ADARs 
First, to investigate if the reduced luciferase activity of pmirGLO-
METTL7A-3’UTR upon ADARs overexpression was the direct consequence of 
extensive 3’UTR editing, we substituted multiple adenines with guanines in 
METTL7A 3’UTR to mimic the effects of inosine by generating different A-to-
G mutants of pmirGLO-METTL7A-3’UTR (Figure 5-1A). The different A-to-
G mutants of pmirGLO-METTL7A-3’UTR were generated by cloning of 
METTL7A 3’UTR using cDNA of HEK-293 cells with overexpression of 
ADARs. Surprisingly, no significant difference in the luciferase activities 
between different A-to-G mutants was observed (P = 0.57) (Figure 5-1B). This 
suggested for the first time that the previously observed reduction in the 
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luciferase activity of pmirGLO-METTL7A-3’UTR upon ADARs 
overexpression might be independent of ADARs editing activity.  
 
Figure 5-1 Luciferase reporter assay of different A-to-G mutants of 
pmirGLO-METTL7A-3’UTR. (A) Multiple sequence alignment of different 
A-to-G mutant constructs of pmirGLO-METTL7A-3’UTR and wild type 
METTL7A 3’UTR. Mutation of A to G is highlighted in yellow. (B) Luciferase 
activities of different A-to-G mutants of pmirGLO-METTL7A-3’UTR. RLU, 
relative luminescence unit.  
 
Even though inosine could be interpreted as guanosine by certain cellular 
machineries, the A-to-G mutants of pmirGLO-METTL7A-3’UTR could not 
recapitulate all of the inosine associated effects because certain proteins 
recognize inosine only but not guanosine (Zhang & Carmichael, 2001). To 
dissect the precise regulatory role of 3’UTR editing on METTL7A expression, 
we generated different ADARs mutants to abolish either the enzymatic activity 
or the dsRNA binding ability of ADARs (Figure 5-2). To abolish the 
enzymatic activity, ADARs DeAminase Domain were mutated (referred as 
DeAD mutant) by introducing specific point mutations (ADAR1: H910Y and 
E912A; ADAR2: E396A) (Lai et al., 1995). To abolish the dsRNA binding 





(referred as EAA mutant) by introducing 3 point mutations converting the 
conserved Lysine (K) to Glutamate (E) or Alanine (A) (Valente & Nishikura, 
2007). The editing activities of different ADARs mutants were determined by 
co-transfection with pmirGLO-METTL7A-3’UTR into HEK-293 cells and 
liver cancer cell line SNU-398. Editing frequencies of the selected 10 
representative editing sites of METTL7A 3’UTR mentioned above were 
measured by Sanger sequencing (Figure 5-3). Compared to wild type ADARs 
which increased the editing level of METTL7A 3’UTR, ADARs DeAD mutants 
surprisingly inhibited the basal editing level of METTL7A 3’UTR, and the basal 
editing level was the editing frequency observed when only empty vector was 
used in the co-transfection experiment. This suggested that ADARs DeAD 
mutants functioned as dominant negative forms, probably because they still 
retain the homodimerization abilities, can compete for homodimerizing with 
the endogenous wild type ADARs, and thereby suppress the basal editing 
activity of endogenous ADARs (Valente & Nishikura, 2007). Alternatively, 
ADARs DeAD mutants can still bind to METTL7A mRNA, but are not able to 
edit it. Hence ADARs DeAD mutants can function as dominant negative forms 
by precipitating the editing substrates from the wild type ADARs. Interestingly, 
ADARs EAA mutants did not significantly alter the basal editing level of 
METTL7A 3’UTR compared to the empty vector control (P = 0.14 for ADAR1 
EAA, and P = 0.47 for ADAR2 EAA) (Figure 5-3). This might be attributed 
to the loss of dimerization ability of the EAA mutants, since the DRBD has 
been reported to be involved in the homodimerization of ADARs (Poulsen et 
al., 2006). The loss of binding to dsRNA by ADARs EAA mutants also 
explains the absence of competition between EAA mutants and wild type 
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ADARs. Representative chromatograms of 2 editing sites in METTL7A 
3’UTR from both HEK-293 and SNU-398 cells reflecting the dominant 
negative effects of ADARs DeAD mutants and the neutral effects of ADAR 
EAA mutants are shown (Figure 5-4 and Figure 5-5). Similarly, the editing 
frequencies of the indicated editing sites were calculated from the ratio of the 
area under G peak to the sum of the area under G and A peaks. 
 
Figure 5-2 Schematic diagram of wild type and mutant ADARs. ADARs 
DeAD mutants (DeAminase Domain mutants) carry point mutations introduced 
to the deaminase domain (H910Y|E912A for ADAR1, and E396A for ADAR2), 
while ADARs EAA mutants (dsRNA binding domain mutants) harbour 
mutations of KKXXK to EAXXA in all dsRNA binding domains (DRBDs). 
 
 
Figure 5-3 The editing activities of different ADARs mutants in HEK-293 
and SNU-398 cells. The RNA editing frequency of METTL7A 3’UTR was 
measured for the 10 representative editing sites by Sanger sequencing. 
pmirGLO-METTL7A-3’UTR was co-transfected with the wide type and 
different mutant ADARs in both cell types: (A) HEK-293 cells, and (B) SNU-





Figure 5-4 Chromatogram of 2 editing sites in METTL7A 3’UTR upon wild 
type and mutant ADARs overexpression in HEK-293 cells. PCR was 
performed with cDNA generated from HEK-293 cells co-transfected with 
pmirGLO-METTL7A-3’UTR and different ADARs constructs indicated in the 
figure. PCR products were sent for Sanger sequencing, and 2 of the 10 
representative editing sites of METTL7A 3’UTR were shown. Values indicate 
the editing frequencies. DeAD, DeAminase Domain mutants; EAA; dsRNA 




Figure 5-5 Chromatogram of 2 editing sites in METTL7A 3’UTR upon wild 
type and mutant ADARs overexpression in SNU-398 cells. Similar to Figure 
5-4, the experiment was performed in liver cancer cell line SNU-398. 
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5.2 Editing-independent suppression of ADARs on METT7A  
To confirm the editing-independent regulation of METTL7A 3’UTR by 
ADARs, we repeated the luciferase assay for pmirGLO-METTL7A-3’UTR in 
HEK-293 cells, but including both the wild type and different mutant ADARs 
this time. Indeed, the suppression of METTL7A 3’UTR by wild type ADARs 
was persistent for the DeAminase Domain and DRBD mutants of ADARs 
(Figure 5-6). The reduced luciferase activities observed for all forms of 
ADARs (wild type and mutant forms) confirmed the editing-independent 
regulation of ADARs on METTL7A 3’UTR.  
In addition to the luciferase reporter, we also developed another reporter 
system which fused the green fluorescent protein (GFP) to the 5’ of METTL7A 
open reading frame (ORF) followed by METTL7A 3’UTR sequence. This 
system allowed us to study the regulation of ADARs on METTL7A 3’UTR by 
immunoblotting. Consistent to the luciferase assay, overexpression of all 
ADAR forms, including the wild-type and all the mutants, repressed the 
expression of GFP-METTL7A in the HCC cell line SNU-398 which had been 
established for constitutive expression of the GFP-METTL7A-3’UTR 
construct (Figure 5-7). HEK-293 cells were not used for this assay because of 
its intrinsic resistance to the antibiotic geneticin which was used for selection 
of cells with stable expression of GFP-METTL7A-3’UTR construct. In 
conclusion, both the luciferase assay and the GFP-METTL7A fusion reporter 




Figure 5-6 Luciferase assay of pmirGLO-METTL7A-3’UTR with 
overexpression of different ADARs including the wild type and mutants 
(deaminase domain and DRBD mutants) in HEK-293 cells. pmirGLO-
METTL7A-3’UTR was co-transfected with different ADARs in HEK-293 cells, 
and luciferase activity was measured 48 hours post transfection. RLU, relative 
luminescence unit; EV, empty vector; DeAD, DeAminase Domain mutant; 
EAA, dsRNA binding domain mutant.  
 
 
Figure 5-7 Regulation of GFP-METTL7A-3’UTR by different ADARs 
including the wile type and mutants in SNU-398 cells. Top: schematic 
diagram of GFP-METTL7A-3’UTR reporter construct. Bottom: immunoblots of 
the indicated proteins upon overexpression of different ADARs in HCC cell 





To complement the exogenous reporter assays, we further investigated if 
ADARs also regulate the endogenous METTL7A through an editing-
independent mechanism. Due to their neutral effects on METTL7A 3’UTR 
editing, only ADARs EAA mutants were included in the following experiments. 
Frist, we tested the specificity of anti-METTL7A antibody by transfection of 
HEK-293 cells with a METTL7A overexpressing construct. As indicated by 
the immunoblot, anit-METTL7A antibody detected the protein with specificity 
at the predicted molecular weight (around 28 kDa) (Figure 5-8A). We further 
checked the expression of METTL7A protein across different HCC cell lines 
with this antibody in order to choose the appropriate cell lines for the 
downstream mechanistic and functional studies (Figure 5-8B). Finally we 
chose HuH-7 cells for the mechanistic study given its medium level of 
METTL7A expression.  
 
Figure 5-8 Specificity test of anti-METTL7A antibody in HEK-293 cells 
and expression of METT7A in different HCC cell lines. (A) HEK-293 cells 
were transfected with either empty vector (EV) or METTL7A overexpressing 
vector. Total cell lysate was used to test the specificity of anti-METTL7A 
antibody. The antibody detected a specific band at the predicted METTL7A 
molecular weight (28 kDa). (B) Expression of METTL7A was checked with the 





Consistent to the reporter assays (Figure 5-6 and Figure 5-7), both the 
wild type and EAA mutants of ADARs inhibited endogenous METTL7A 
expression in HCC cell line HuH-7 (Figure 5-9A and B). However no obvious 
change in METTL7A mRNA expression was observed, suggesting a post-
transcriptional regulation by ADARs (Figure 5-9C). Similarly, constitutive 
expression of ADARs in another cell line SMMC-7721 also demonstrated the 
suppressive effects of ADARs on METTL7A expression (Figure 5-9D). 
Conversely, shRNA-mediated knockdown of either ADAR1 or ADAR2 
induced METTL7A protein expression in SMMC-7721 or HuH-7 cells, 
respectively (Figure 5-10). Taken together, ADARs indeed exerted an editing-





Figure 5-9 Inhibition of endogenous METTL7A expression by ADARs 
independent of their editing activities. (A) Immunoblots of the indicated 
proteins 72 hours after transfection of ADARs wild type and EAA mutants 
(dsRNA binding domain mutants) in HCC cell line HuH-7. Values indicate the 
normalized band intensities for METTL7A against tubulin. EV, empty vector. 
(B) Densitometric analysis (mean ± SEM) of the immunoblots as in (A). (n = 5; 
*P < 0.05; ***P < 0.001). (C) qPCR of METTL7A mRNA (mean ± SEM) 
measured for the same experiment of (A). (D) Immunoblots of the indicated 
proteins of SMMC-7721 with constitutive expression of wild type ADARs. 
 
 
Figure 5-10 Induction of METTL7A expression by shRNA mediated 
knockdown of ADARs. Immunoblots of the indicated proteins upon lentiviral 
mediated knockdown of ADAR1 and ADAR2 in HCC cell line SMMC-7721 
and HuH-7, respectively. Normalized band intensity for METTL7A against 






5.3 MiR-27a and miR-27b target METTL7A 3’UTR 
Editing-independent functions of ADARs were first delineated in 
Drosophila, where ADARs were shown to regulate RNAi and miRNA 
processing independent of their editing activities (Heale et al., 2009). Recently, 
such editing-independent effects of ADARs on RNAi and miRNA processing 
have also been observed in mammalian systems, but only limited to ADAR1 
(Ota et al., 2013). In light of the fact that 3’UTR is the major region of miRNA 
targeting, miRNAs are likely to mediate the editing-independent effects of both 
ADAR1 and ADAR2 on METTL7A expression. 
To identify the miRNAs targeting METTL7A 3’UTR, METTL7A 3’UTR 
sequence was subjected to miRNA prediction by miRWalk across multiple 
algorithms (miRanda, miRDB, miRWalk, RNA22 and Targetscan) (Dweep et 
al., 2011). Only miRNAs predicted by at least two algorithms were selected 
and cloned into pMIRNA1 for validation of targeting the luciferase reporter 
pmirGLO-METTL7A-3’UTR in HEK-293 cells. In addition to the prediction, 
miRNAs were also checked for the expression change in the small RNA-seq 
data obtained from ADAR1-/- mouse embryos. Reduced miRNA expression 
upon ADAR1 knock out suggests a potential agonistic regulation of the 
predicted miRNAs by ADAR1, which assisted to further filter the predicted 
miRNAs in order to identify the true mediators between ADARs and 
METTL7A. The final list of miRNAs selected for validation was shown in 
Table 5-1. 
Among the predicted miRNAs, miR-27a and miR-27b were shown to 
significantly reduce pmirGLO-METTL7A-3’UTR luciferase activity (Figure 
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5-11). Furthermore, both miR-27a and miR-27b could suppress pmirGLO-
METTL7A-3’UTR luciferase activity in a dose-dependent manner (Figure 
5-12A). More importantly, we introduced mutations to the miR-27a/b targeting 
sequence of METTL7A 3’UTR as indicated in Figure 5-12B. Compared to the 
wild type, mutant METTL7A 3’UTR was shown to be immune to miR-27a/b 
mediated repression, confirming that miR-27a/b directly bind to METTL7A 
3’UTR and repress its expression (Figure 5-12C). Lastly, we also 
demonstrated that miR-27a/b could inhibit endogenous METTL7A protein 
expression in HuH-7 cells without affecting its mRNA levels (Figure 5-13). 
Most of our experiments were conducted with overexpression of ADARs 
which can potentially induce A-to-I editing to METTL7A 3’UTR and/or miR-
27a/b sequences. The editing of either METTL7A 3’UTR or miR-27a/b can 
potentially abolish the targeting of METTL7A by miR-27a/b. Therefore it is 
important to check the editing status of miR-27a/b targeting site of METTL7A 
3’UTR as well as the mature miR-27a/b sequence. By Sanger sequencing of the 
cDNA of HuH-7 cells with overexpression of wild type and mutant ADARs, we 
confirmed that the predicted miR-27a/b targeting site in METTL7A 3’UTR was 
free of RNA editing, so was miR-27a itself (Figure 5-14). miR-27a/b were 
predicted to target the tip of METTL7A 3’UTR, a region free of any repetitive 
element (Figure 5-11). Hence it is unlikely that the predicted miR-27a/b 
targeting site in METTL7A 3’UTR is involved in any dsRNA secondary 
structure formation. This explains why there is no editing in this region even 




Table 5-1 miRNAs predicted to target METTL7A 3’UTR. 
miRNA miRanda miRDB miRWalk RNA22 Target
scan 
SUM Expression change in 
ADAR1-/- mouse embryos 
hsa-miR-612 1 1 0 0 1 3   
hsa-miR-17 1 0 0 0 1 2 10 fold reduction 
hsa-miR-940 1 0 0 0 1 2   
hsa-miR-20b 1 0 0 0 1 2   
hsa-miR-654-5p 1 0 0 0 1 2   
hsa-miR-93 1 0 0 0 1 2 8 fold reduction 
hsa-miR-610 1 0 0 0 1 2   
hsa-miR-637 1 0 0 0 0 1   
hsa-miR-27a 1 0 0 0 1 2  




Figure 5-11 Validation of the predicted miRNAs for targeting METTL7A 
3’UTR. Top: schematic diagram showing the predicted miR-27a/b targeting 
position on METTL7A 3’UTR. The predicted miR27a/b targeting site does not 
belong to any Alu element in METTL7A 3’UTR. Bottom: luciferase activity 
(mean ± SEM) of pmirGLO-METTL7A 3’UTR 48 hours after co-transfection 
with the indicated miRNAs (predicted by miRWalk) at a mass ratio of 1:9 into 
HEK-293 cells. pMIRNA1, empty vector; miR-93 scr, scrambled control 
(scrambled mature miR-93 seed sequence). RLU, relative luminescence. (n = 6; 




Figure 5-12 miR27a/b as the direct repressors of METTL7A 3’UTR. (A) 
Luciferase activity (mean ± SEM) of pmirGLO-METTL7A 3’UTR 48 hours 
after co-transfection with increasing amounts of miR-27a/b into HEK-293 cells. 
RLU, relative luminescence. (n = 6; ***P < 0.001). (B) Schematic diagram 
showing the predicted base-paring between the wild type METTL7A 3’UTR and 
miR-27a/b. Mut METTL7A-3’UTR shows the mutations introduced into the 
miR-27a/b targeting region, as highlighted in yellow. WT, wild type; Mut, 
mutant. (C) Luciferase activities (mean ± SEM) of the wild type and mutant 
pmirGLO-METTL7A 3’UTR 48 hours after co-transfection with miR-27a/b into 




Figure 5-13 miR-27a/b inhibit endogenous METTL7A protein expression 
in HuH-7 cells. (A) Immunoblots of the indicated proteins after lentiviral 
overexpression of miR-27a/b in HCC cell HuH-7. (B) Densitometric analysis 
(mean ± SEM) of the immunoblots in (A) (n = 5; **P < 0.01). (C) qPCR of 







Figure 5-14 Editing status of the predicted miR-27a/b targeting site in 
METTL7A 3’UTR as well as the mature miR-27a sequence in HuH-7 cells. 
(A) Sequencing chromatograms of the predicted miR-27a/b targeting site of 
METTL7A 3’UTR in HuH-7 cells with overexpression ADARs. EV, empty 
vector, showing absence of editing in this region. (B) Sequencing 
chromatograms of mature miR-27a sequence in HuH-7 cells with 
overexpression of both wild type and mutant ADARs, also showing the absence 





5.4 ADARs augment miR-27a expression independent of 
RNA editing activity through the interaction with Dicer  
We have demonstrated that miR-27a/b could directly inhibit METTL7A 
expression. If miR-27a/b were indeed the editing-independent mediators 
between ADARs and METTL7A, we would expect to observe the editing-
independent regulation of miR-27a/b expression by ADARs. Indeed, 
overexpression of different ADARs (wild type and EAA mutants) in HuH-7 
cells all increased the expression of miR-27a (Figure 5-15A). However for 
miR-27b, only wild type ADAR1 enhanced its expression upon overexpression, 
but not the ADAR2, neither the EAA mutants of ADAR1 and ADAR2 (Figure 
5-15B). Therefore, we propose that miR-27a but not miR-27b functions as the 
editing-independent link between ADARs and METTL7A.  
To study which stage along the miR-27a maturation is regulated by 
ADARs, we further quantified the expression of miR-27a precursors including 
the pre-miR-27a and pri-miR-27a by qPCR. Surprisingly, we did not observe a 
similar increase for either pre-miR-27a or pri-miR-27a in HuH-7 cells upon 
overexpression of both the wild type and EAA mutants of ADARs (Figure 5-
15C and D). The increased expression observed only for the mature miR-27a 
suggests that ADARs enhanced the maturation of miRNAs from pre-miRNAs. 
Maturation of miRNAs from pre-miRNAs is catalysed by Dicer in complex 
with TRBP. Given that ADAR1 has been reported to form a complex with Dicer 
(Ota et al., 2013), we proposed here that ADAR2 could also interact with Dicer 









































































































































Figure 5-15 ADARs enhanced miR-27a expression independent of RNA 
editing activity. Real-time PCR (mean ± SEM) of the indicated target RNAs 
(mean ± SEM) of HuH-7 cells 72 hours after overexpression of wild type and 
mutant ADARs (n=3, *P<0.05, **P < 0.01, ***P<0.001). EV, empty vector; 
EAA, dsRNA binding domain mutant of ADARs.  
 
The interaction between ADARs and Dicer was studied by pull down 
assays. FLAG-tagged wild type and mutant ADARs were overexpressed in 
HEK-293 cells, followed by immunoprecipitation (IP) with anti-FLAG 
antibody. As shown by the immunoblot with anti-FLAG antibody, FLAG-
tagged ADARs were successfully pulled down (Figure 5-16A). More 
importantly, all the FLAG-tagged ADARs also pulled down the endogenous 
Dicer, albeit to a lesser extent for the EAA mutants (Figure 5-16B). Even 
though the EAA mutants of ADARs demonstrated decreased interaction with 
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Dicer, given the similar reduction in METTL7A expression upon 
overexpression of both the wild type and EAA mutants of ADARs, we reckoned 
that the residual interaction between the EAA mutants of ADARs and Dicer 
might be enough to saturate the Dicer activity. Alternatively, the EAA mutants 
of ADARs might work through mechanisms yet to be identified.  
 
Figure 5-16 Interaction between ADARs and Dicer in HEK-293 cells. 
Immunoblots of FLAG pull down products from HEK-293 cells transfected 
with FLAG-tagged ADARs. HEK-293 cells transfected with FLAG only vector 
served as a negative control. (A) With anti-FLAG antibody to show the 
successful pull down of FLAG-tagged ADARs. (B) With anti-Dicer antibody to 




There have been reports regarding to the subcellular localization of 
ADARs. ADAR1 has been reported to be able to translocate between the 
cytoplasm and nucleus. However, ADAR2 was reported to be mainly localized 
in the nucleus (Ota et al., 2013). The nuclear localization of ADAR2 raised 
questions about its interaction with Dicer complex which catalyses the pre-
miRNA processing in the cytoplasm. To resolve this discrepancy, we performed 
nuclear fractionation of HEK-293 cells after overexpressing FLAG-tagged 
ADARs (Figure 5-17). Immunoblots with anti-α-tubulin and anti-fibrillarin 
antibodies indicated successful nuclear fractionation of HEK-293 cells, and 
immunoblots with anti-FLAG and anti-Dicer antibodies demonstrated that 
FALG-tagged ADARs and Dicer presented in both the cytoplasm and nucleus. 
The concurrence of FLAG-tagged ADARs and Dicer in the same cellular 
compartments made their interaction possible. However the presence of FLAG-
tagged ADARs in both the cytoplasm and nucleus seemed to be inconsistent 
with previous studies. We noticed that previous studies were performed with 
endogenous ADARs proteins. Therefore, to investigate if endogenous ADARs 
have a different subcellular distribution pattern compared to the overexpressed 
FLAG-tagged ADARs, We performed nuclear fractionation with native HuH-7 
cells. To our surprise, we found that both endogenous ADAR1 and ADAR2 
localized mainly in the nucleus (Figure 5-18). Therefore in comparison to the 
endogenous ADARs, we observed spill over effects of the overexpressed 
FLAG-tagged ADARs in HEK-293 cells. ADARs over flowed to the cytoplasm 
from nucleus upon overexpression, which led to the interaction with Dicer and 
promoted miRNA processing. Therefore overexpression of ADARs in this 
study might lead to some artificial observations, but shRNA-mediated ADARs 
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knockdown compensated the artificial overexpression system and confirmed the 
findings associated with overexpression of ADARs.  
 
 
Figure 5-17 Nuclear fractionation of HEK-293 cells with overexpression of 
FLAG-tagged ADARs. Immunoblots of the indicated proteins of HEK-293 
cells with overexpression of FLAG-tagged ADARs. Nuclear fractionation was 
performed 48 hours after transfection of HEK-293 cells. α-tubulin is a 
cytoplasmic protein, while fibrillarin is a nuclear protein.  
 
 
Figure 5-18 Nuclear 
fractionation of HuH-7 cells. 
Immunoblots of the indicated 
endogenous proteins of HuH-7 
cells. α-tubulin is a cytoplasmic 
























5.5 Global regulations of ADARs on miRNA processing  
Moving on from the gene specific study with METTL7A and miR-27a, 
we are interested to study if ADARs have some global effects on miRNA 
processing through the interaction with Dicer. We performed the global miRNA 
expression profiling for HuH-7 cells transfected with both the wild type and 
ADARs EAA mutants with a microarray system from Exiqon. Unsupervised 
global clustering of the obtained miRNA expression data revealed that ADARs 
wild type and EAA mutants formed separate clusters for both ADAR1 and 
ADAR2 (Figure 5-19). Moreover the EAA mutants transfected HuH-7 cells 
seemed to cluster together with the empty vector transfected HuH-7 cells, 
indicating that the editing activity of ADARs still played the predominant role 
on regulating miRNA expression. 
Figure 5-19 Unsupervised 
clustering of miRNA expression 
change upon ADARs 
overexpression in HuH-7 cells. 
HuH7-cells with different ADARs 
overexpression are clustered based 
on the miRNA expression change 
measured 72 hours after 
transfection by Exiqon's 
miRCURY LNA™ microRNA 
Array. Figure by Dr. Henry Yang. 
 
In order to identify the miRNAs regulated by ADARs in an editing 
dependent or independent manner, we performed a supervised clustering 
analysis by using Cluster and TreeView program (Eisen et al., 1998) (Figure 
5-20). Only miRNAs demonstrating at least 1.5 fold changes in expression upon 
ADARs overexpression were included into this analysis. Editing independently 
regulated group was defined as those miRNAs which demonstrated expression 
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changes with overexpression of both the wild type and EAA mutants of ADARs. 
Conversely, the editing dependently regulated group was defined as those 
miRNAs which only demonstrated expression changes with overexpression of 
the wild type ADARs but not the EAA mutants. In total, we identified 31 and 
44 miRNAs editing independently regulated by ADAR1 and ADAR2 
respectively, as well as 30 and 26 miRNA editing dependently regulated by 
ADAR1 and ADAR2 respectively (Figure 5-21). Among the miRNAs showing 
at least 1.5 fold expression changes, editing independent functions of ADARs 
seemed to play a major role in regulating their expression, especially for 
ADAR2. However, unlike miR-27a, ADARs did not demonstrate a general 
enhancing effect on miRNA expression. Rather, they can both enhance and 
suppress miRNA expression to a similar extent.     
Figure 5-20 Supervised 
clustering of miRNA 
expression changes of HuH-7 
cells with different ADARs 
overexpression. Only miRNAs 
showing at least 1.5 fold 
expression changes upon 
ADARs overexpression were 
included into this analysing by 
Cluster and TreeeView program. 
Editing independent group of 
miRNAs was defined as those 
with expression changes 
observed upon overexpression 
of both the wild type and EAA 
mutants of ADARs. Conversely, 
the editing dependent group of 
miRNAs was defined as those 
with expression changes 
observed upon overexpression 
of only the wild type ADARs, 
but not the EAA mutants. EV, 
empty vector; WT, wild type; 





Figure 5-21 miRNAs regulated by ADARs in editing dependent and 
independent manners. Number of miRNAs was summarized from Figure 
5-20.  
 
To verify the reliability of our dataset, we intersected the miRNAs 
regulated by ADAR1 and ADAR2 for both the editing independent and 
dependent groups (Oliveros, 2007) (Figure 5-22). 16 miRNAs were found to 
be commonly regulated by both ADAR1 and ADAR2 in an editing independent 
manner; however no shared miRNA was found to be regulated by ADAR1 and 
ADAR2 in an editing dependent manner. This might be explained by the distinct 
substrate specificities of ADAR1 and ADAR2 as editing enzymes. For the 
interest of our study to identify the editing independent regulation mechanisms 
of ADARs on miRNA expression, we chose to validate a few miRNAs from the 
editing independent group of miRNAs commonly regulated by ADAR1 and 
ADAR2. The miRNAs chosen for validation by qPCR were miR-23a, miR-135a, 
and miR-200a. miR-23a was shown to be downregulated by both ADAR1 and 
ADAR2 in the microarray profiling, while miR-135a and miR-200a were shown 
to be upregulated by ADAR1 and ADAR2. In contrast to the microarray system, 
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qPCR failed to demonstrate similar changes of the selected miRNAs, except for 
miR-23a whose downregulation by ADAR2 EAA mutant was confirmed by 
qPCR (Figure 5-23). Even though we have only tried to validate the microarray 
data with 3 selected miRNAs, based on this preliminary finding, we concluded 
that the microarray data was not reliable, and ceased for further analysis of the 
dataset. The failed microarray expression profiling experiment might be 
attributed to the low and transient overexpression of ADARs by transfection. In 
future, if repeated experiment is needed, lentiviral mediated overexpression of 
ADARs should be considered. 
 
Figure 5-22 Intersection of miRNAs regulated by ADAR1 and ADAR2. 
miRNAs were first defined as editing independent group or editing dependent 
group as described above (Figure 5-20), and then intersected between ADAR1 














































































































Figure 5-23 Validation of the selected miRNAs from the microarray 
expression data by qPCR. miRNAs were selected based on the intersection 
between ADAR1 and ADAR2 (Figure 5-22). All the three selected miRNAs 
were regulated by both ADAR1 and ADAR2 independent of their editing 
activities; however only miR-23a was confirmed to be downregulated by 
ADAR2 EAA mutant. The same cDNA of HuH-7 cells with different ADARs 
overexpression sent for miRNA microarray experiment was used for this 




 METTL7A FUNCTIONS AS A 
NOVEL TUMOR SUPPRESSOR IN HCC 
6.1 Introduction 
The name of METTL7A, Methyltransferase-Like protein 7A, suggests 
there might be methyltransferase activity associated with it. However 
METTL7A is a poorly studied protein with a previously used name of AAM-B 
(Zehmer et al., 2008a). Little is known about its biochemical activities and no 
methylated substrate has been identified for METTL7A.  
METTL7A was identified as a lipid droplet associated protein in a 
proteomic screen of by Zehmer et al. (Zehmer et al., 2008a). It was shown to be 
preferentially targeted to lipid droplets, but could be accumulated at the 
endoplasmic reticulum (ER) given a high level of expression. METTL7A was 
predicted to have multiple domains (Figure 6-1). The N-terminal hydrophobic 
domain of METTL7A consists of 28 amino acid, which is necessary and 
sufficient to target METTL7A to the lipid droplets (Zehmer et al., 2008a). 
Downstream of the hydrophobic domain, the juxtamembrane domain contains 
amino acids which can enhance the lipid droplet targeting efficiency of 
METTL7A. Lastly, based on sequence homology, METTL7A is predicted to 
possess an S-adenosylmethionine-dependent methyltransferases domain (SAM). 
 
HyD JuxtaM SAM 
Figure 6-1 The functional domains of METTL7A. METTL7A consists of an 
N-terminal hydrophobic domain (HyD), a juxtamembrane domain (JuxtaM), 
and a predicted S-adenosylmethionine-dependent methyltransferases domain 




METTL7A has a close paralog, METTL7B, also known as ALD1 
(associated with lipid droplet protein 1). METTL7B was also identified as a 
lipid droplet targeting protein in a proteomic screen of proteins associated with 
hepatic lipid droplets (Ingelmo-torres et al., 2006). The N-terminal hydrophobic 
domain, which is necessary for lipid droplet targeting, is highly conserved 




Both METTL7A and METTL7B have been predicted to be protein 
arginine methyltransferases (PRMTs), and clustered to the same branch as 
ALKBH8 (Figure 6-3) (Sheppard et al., 2011). ALKBH8 was reported to be a 
tRNA methyltransferase to methylate uridines at the wobble position of certain 
tRNAs (Fu et al., 2010). The close phylogenetic relationship of METTL7A and 
METTL7B with ALKBH8 suggests that certain tRNAs could be the potential 
methylated substrates of METTL7A and METTL7B.  
Figure 6-2 Sequence alignment of the N-terminal hydrophobic domains of 
METTL7A and METTL7B. Hydrophobic amino acids were in gray, acidic 
amino acids were in red, and basic amio acids were in blue. Proline residue is
specifically highlighted for its potential involvement in the formation of




Figure 6-3 The phylogenetic tree of 45 predicted human protein arginine 
methyltransferases (PRMTs). PRMTs with validated activities are 
highlighted in blue. Enzymes with validated RNA methyltransferase activities 
are highlighted in green. METTL7A and METTL7A are highlighted in the red 
circle. They are clustered to the same branch as ALKBH8 which was validated 




6.2 METTL7A expression in primary HCC patient samples 
Despite the well-described editing-dependent functions of ADARs in 
HCC development (Chan et al., 2013), the editing-independent regulation of 
METTL7A by ADARs prompted us to study the involvement of METTL7A in 
HCC development. At the beginning our study, in order to select an interesting 
candidate gene, we had checked the expression of METTL7A mRNA across 
different cancers from a publically available database called GENT (Gene 
Expression across Normal and Tumor tissue, http://medical-gen
ome.kribb.re.kr/GENT/) (Shin et al., 2011). Interestingly, METTL7A displayed 
a general reduction of expression in different cancers (Figure 6-4). Specifically 
for liver cancer, we also retrieved the METTL7A expression data, which 
showed the loss of METTL7A expression in liver cancer (Figure 6-5). The 
reduced expression of METTL7A across different cancers strongly suggests that 
METTL7A functions as a tumor suppressor.  
 
Figure 6-4 METTL7A expression of the normal and tumor tissues from 
different cancers. Expression data were retrieved from the publically available 








To confirm the reduced expression of METTL7A during liver cancer 
development. We further accessed two more publically available expression 
databases: the RNA-seq data from TCGA (LIHC) with 377 cases (https://tcga-
data.nci.nih.gov/tcga/) and the microarray gene expression data from 
GEO54236 with 161 cases (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc=GSE54236) (Villa et al., 2015). Both datasets showed consistently that 
METTL7A expression was reduced in HCC tumor samples compared to the 
matched normal or non-tumorous tissues (Figure 6-6). Moreover, to 
investigate if there is any clinical implication associated with the reduced 
expression of METTL7A in tumor samples, Kaplan-Meier survival analysis was 
performed after classifying patients into METTL7A-low and METTL7A-high 
groups. Patients were first classified using the median expression of tumor 
METTL7A into high and low groups, and then the middle samples with 
expression levels of 87% higher and 115% lower than the median expression 
value were removed to minimize the false classification due to potential 
measurement variations. As shown in Figure 6-7, both TCGA and GEO54236 
datasets revealed the consistent result that lower METTL7A expression in 
















expression in liver cancer. 
The value of METTL7A
mRNA expression level was 
retrieved from the database 





METTL7A-low HCC patients also showed a poorer prognosis of the tumor-free 
survival, as reflected by the TCGA dataset. 
 
Figure 6-6 METTL7A expression in HCC from two publically available 
databases. For data from TCGA, raw RNA-seq counts were normalized using 
the total numbers of mappable reads across all samples, while the array data 
normalization of GEO54236 was performed using the Cross-Correlation 















































Figure 6-7 The prognostic value of METTL7A expression on HCC patient 
survival status. METTL7A-high and -low groups were defined based on the 
median expression of tumor METTL7A, and the middle samples having 
METTL7A expression levels of 87% higher and 115% lower than the median 
expression value were removed to minimize the false classification due to 
potential measurement variations. Survival curves were generated using the 
Kaplan-Meier method and compared statistically using the log rank test. (A) 
Overall survival analysis from the TCGA dataset. (B) Tumor-free survival 
analysis from the TCGA dataset. (C) Overall survival analysis from GEO54236 
dataset. Figure credit: Dr. Henry Yang. 
 
The reduced expression of METTL7A in HCC tumors identified from the 
publically available databases was further confirmed using our in-house HCC 
tissue bank. The expression of METTL7A mRNA from 96 pairs of HCC tumor 
and their adjacent NT liver specimens was measured by qPCR. Consistent to 
the public databases, HCC tumors demonstrated significantly lower expression 
of METTL7A than the adjacent NT specimens (Figure 6-8A). Furthermore, the 
prognostic value of METTL7A expression on HCC patient clinical outcomes 
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was also validated. Since the expression of METTL7A was quantified by 
ourselves with strict control of experimental variations, HCC patients can be 
confidently classified into METTL7A-low and METTL7A-high groups based 
on the median expression of METTL7A in HCC tumors. Based on this standard, 
44 HCC patients were classified into METTL7A-high group, and 41 of them 
were classified into METTL7A-low group. Kaplan-Meier survival analysis 
revealed that the METTL7A-low group demonstrated significantly shorter 
overall survival (OS) than the METTL7A-high group (mean OS: 50.4 and 81.5 
months for the METTL7A-low and METTL7A-high group, respectively; P = 
0.009) (Figure 6-8B). However, there was no significant difference in the 
tumor-free survival probability between the two groups (Figure 6-8C). In the 
univariate Cox analysis, the statistically significant predictors for patients’ OS 
were the status of vascular invasion (P = 0.017), TNM staging of the patients 
(P < 0.001), recurrence or metastasis status (P = 0.003), and tumor METTL7A 
mRNA expression (P = 0.015). In the multivariate Cox analysis, tumor 
METTL7A mRNA expression level was shown to be an independent predictor 
for patients’ OS (P = 0.015, HR: 0.314; 95% CI: 0.124 to 0.789) (Table 6-1). 
In combination with the discoveries made from the publically available 
databases, we proposed that METTL7A may function as a novel tumor 




Figure 6-8 METTL7A expression of HCC patient samples from the in-house 
tissue bank. (A) METTL7A expression of 96 pairs of HCC tumors and the 
matched adjacent non-tumorous tissues, measured by qPCR. ***P<0.001. (B) 
Kaplan-Meier analysis of the overall survival probability of HCC patients 
categorized based on the median expression of METTL7A mRNA in HCC 
tumors. The blue line represents METTL7A-low patients (n = 41), with tumor 
METTL7A mRNA expression lower than the median expression level; and vice 
versa for the METTL7A-high patients (red line; n = 44). (Log rank test). (C) 
Kaplan-Meier analysis of the tumor-free survival probability of HCC patients. 
Classification of HCC patients into METTL7A-low and METTL7A-high 






Table 6-1 Multivariate Cox regression analysis of the significant predictors 
for HCC patients’ overall survival probability. 
Predictors Sig.a HRb 95% CIc for HR 
Lower Upper 
Vascular Invasion 0.287 1.462 0.727 2.940 
TNM staging 0.008 1.792 1.161 2.767 
Recurrence or 
Metastasis 
0.002 4.814 1.762 13.151 
Tumor METTL7A 
mRNA expression 
0.015 0.314 0.124 0.798 
a, Statistical Significance (P < 0.05) 
b, Hazard Ratio 




6.3 Tumor suppressive functions of METTL7A in vitro and in 
vivo 
To study the involvement of METTL7A in HCC development, we used 
both gain of function and loss of function approaches with various in vitro and 
in vivo assays.  
For gain of function study, METTL7A was constitutively expressed in 
HCC cell line SNU-398, and SNU-398 was chosen for overexpression because 
of its undetectable level of METTL7A expression measured by qPCR (Figure 
6-9A). Western blot showed the successful overexpression of METTL7A in 
SNU-398 cells (Figure 6-9B). Overexpression of METTL7A significantly 
reduced the cell proliferation of SNU-398 as measured by XTT (2,3-bis-(2-
methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide) assay 
(Figure 6-10A). Flow cytometric analysis of cell cycle with propidium iodide 
(PI) DNA staining indicated that METTL7A overexpression led to G0/G1 
phase arrest of SNU-398 cells (Figure 6-10B). In addition to the cell 
proliferation, the malignancies of SNU-398 cells with constitutive expression 
of METTL7A, as reflected by the focus formation assay and the soft agar 
colony formation assay, were also significantly reduced. Focus formation assay 
assesses the ability of cells to grow without contact inhibition, one of the 
transforming characteristics of cancer cells. Overexpression of METTL7A 
significantly reduced the number of colonies formed by SNU-398 cells in the 
focus formation assay (Figure 6-11A). Soft agar colony formation assay 
measures the anchorage-independent cell growth, one of the hall marks of 
cancer cells too. Similarly, METTL7A overexpression resulted in a 
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significantly lower number of colonies formed by SNU-398 in this assay 
(Figure 6-11B). Most importantly, the xenograft model also confirmed the 
reduced malignancy of SNU-398 cells with constitutive expression of 
METTL7A. Not only did the tumors derived from SNU-398 METTL7A cells 
grow much slower than the tumors derived from SNU-398 EV cells during the 
3-week observation period, but also the tumor volume was significantly smaller 
for SNU-398 METTL7A cells than the SNU-398 EV cells at the end of 3-week 
observation period (Figure 6-12).  
 
Figure 6-9 Constitutive expression of METTL7A in SNU-398 cell. (A) 
METTL7A mRNA expression of different HCC cell lines, measured by qPCR. 
(B) Immunoblot of the indicated proteins indicating the successful 








Figure 6-10 Cell proliferation and cell cycle analysis of SNU-398 cells with 
constitutive expression of METTL7A. (A) Cell proliferation was measured 
based on the activity of the indicated cells to metabolize 2,3-bis-(2-methoxy-4-
nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) into an orange 
formazan dye. The amount of the formazan dye was quantified by the 
absorbance at 490 nm relative to the reference wavelength of 600 nm. EV, 
empty vector. A490nm and A600nm, Absorbance at 490 nm and 600 nm 
respectively. (n=3; ***P < 0.001). (B) Flow cytometric analysis of cell cycle 
with propidium iodide (PI) DNA staining of the indicated stable cells. Values 
indicated the percentage of cells in each cell cycle stage.  
 
 
Figure 6-11 Focus formation assay and soft agar colony formation assay of 
SNU-398 cells with constitutive expression of METTL7A. (A) Focus 
formation assay, 3000 cells of the indicated stable cell lines were cultured for 2 
weeks in 6-well plates, stained with crystal violet, and only colonies with more 
than 50 cells were counted. Quantification was shown on the right panel. (B) 
Soft agar colony formation assay, 5000 cells were seeded in 0.4% of agarose on 
top of a solidified layer of 0.6% of agarose in a 6-well plate. 3 weeks later, 
colonies with more than 50 cells were counted, and summarized in the right 
panel. Scale bar, 400 µm. (n=3; *P < 0.05; ***P < 0.001). 

















Figure 6-12 Xenograft study of SNU-398 cells with constitutive expression 
of METTL7A. 3 million of the indicated stable SNU-398 cell lines were 
injected subcutaneously to the NOD/SCID mice, and observed for 3-week of 
period. (A) The growth curve of tumors derived from the indicated stable SNU-
398 cells. Tumor volume was calculated based on the formula Volume = 0.5 × 
width2 × length. (B) Tumors derived from the indicated stable SNU-398 cells at 
the end of 3-week observation period. EV, empty vector; scale bar, 1 cm.  
 
Complementary to the gain of function studies, loss of function studies 
of METTL7A were also carried out using shRNA mediated knockdown 
approach. HuH-7 cell was chosen as the cell model for METTL7A knockdown 
study given its highest expression of METTL7A mRNA and medium 
expression of METTL7A protein among all the HCC cell lines (Figure 5-8B 
and Figure 6-9A). Lentiviral transduction of shRNAs successfully knocked 
down METTL7A expression in HuH-7 cells (Figure 6-13). Knockdown of 
METTL7A significantly augmented the cell proliferation measured by XTT 
assay; however the focus formation ability of HuH-7 cells was not significantly 
affected by METTL7A knockdown (Figure 6-14). Interestingly, cell invasion 
assay indicated that loss of METTL7A expression increased the cell invasion 
and potentially the metastatic abilities of HuH-7 cells (Figure 6-15). Tumor 
invasion and metastasis involve an important process, known as epithelial-
mesenchymal transition (EMT). EMT is a critical process for normal 
embryonic development, during which epithelial cells acquire the features of 
mesenchymal cells, e.g. increased cell motility and decreased cell adhesions 
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(Yang & Weinberg, 2008). Given the increased cell invasion property of HuH-
7 cells upon METTL7A knockdown, we investigated if EMT contributed to 
this process by studying the expression changes of different EMT markers. Of 
all the proteins we tested, E-cadherin, Claudin, and ZO-1 are markers for the 
epithelial cell origin; while N-cadherin, Vimentin, Snail, Slug, and TCF-8 are 
markers for the mesenchymal cell origin. Among them, only Vimentin 
expression was found to be significantly increased in HuH-7 cells with 
constitutive METTL7A knockdown (Figure 6-16). In addition, the expression 
of Vimentin correlated well with METTL7A expression. Lastly, the xenograft 
studies also demonstrated that bigger tumors were formed by HuH-7 cells with 
loss of METTL7A expression, further confirming the tumor suppressive role 
played by METTL7A in HCC (Figure 6-17). Due to the moderate knockdown 
effect of shMETTL7A_b construct, we first used HuH-7 cells stably transduced 
with this construct for the subcutaneous injection assay. The other two 
shMETTL7A constructs with better knockdown efficiencies should have more 
prominent effects of enhancing the tumorigenicity of HuH-7 cells in vivo, and 
should be tested in future. 
 
 
Figure 6-13 knockdown of METTL7A in HuH-7 cells. Immunoblots of the 
indicated proteins demonstrated successful knockdown of METTL7A in HuH-
7 cells. HuH-7 cells were stably transduced with lentiviruses encoding the 





Figure 6-14 Cell proliferation and focus formation assay of HuH-7 with 
constitutive METTL7A knockdown. (A) Cell proliferation was measured 
based on the activity of the indicated cells to metabolize 2,3-bis-(2-methoxy-4-
nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) into an orange 
formazan dye. The amount of the formazan dye was quantified by the 
absorbance at 490 nm relative to the reference wavelength of 600 nm. EV, 
empty vector. A490nm and A600nm, Absorbance at 490 nm and 600 nm 
respectively. (n=3; ***P < 0.001). (B) Focus formation assay, 3000 cells of the 
indicated stable cell lines were cultured for 2 weeks in 6-well plates, stained 
with crystal violet, and only colonies with more than 50 cells were counted. Scr, 
Scrambled control.  
 
 
Figure 6-15 Invasion assay of HuH-7 cells with constitutive METTL7A 
knockdown. Representative images of the indicated stable cell lines that 
invaded through the Matrigel-coated membrane. 25,000 cells were seeded into 
the rehydrated Matrigel coated chambers. 22 hours later, non-dividing cells 
from the upper surface were removed by scrubbing, and the remaining invaded 
cells were stained with crystal violet. Scr, Scrambled control; scale bar, 200µm. 
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Figure 6-16 Epithelial-Mesenchymal transition (EMT) of HuH-7 cells with 
constitutive METTL7A knockdown. Immunoblots of the indicated proteins 
of HuH-7 cells with stable knockdown of METTL7A. Scr, Scrambled control. 
Vimentin, highlighted in the red rectangle, is the only protein demonstrating 
significantly increased expression with METTL7A knockdown in HuH-7 cells.  
 
 
Figure 6-17 Xenograft studies of HuH-7 cells with constitutive METTL7A 
knockdown. (A) Xenograft tumors derived from the subcutaneous injection of 
indicated stable cell lines into NSG mice with 4-week of observation. No 
subcutaneous tumor was formed by HuH-7 Scr cells in the fifth mouse. Scr, 
Scrambled control. Scale bar, 1 cm. (B) Immunoblots of the indicated proteins 
extracted from the xenograft tumors shown in panel (A). L, left flank injected 
with HuH-7 Scr cells; R, right flank injected with HuH-7 shMETTL7A_b cells. 




6.4 The enzymatic activities of METTL7A 
Methylation is a type of modification that has been observed on all three 
major biological macromolecules: DNAs, RNAs and proteins. METTL7A is 
predicted to have a conserved SAM domain based on the sequence homology, 
and it is interesting to study if there is any methylation enzymatic activity 
associated with METTL7A.  
To study if METTL7A can function as a methyltransferase, we first tested 
proteins as its potential methylation substrates. Histone proteins have been 
reported to undergo a variety of covalent modifications, including methylation, 
acetylation, phosphorylation, and ubiquitination to regulate chromatin 
structures and transcription (Bannister & Kouzarides, 2011; Zhang & Reinberg, 
2001). Therefore histones were first checked for the potential methylation by 
METTL7A. Of histone proteins, only lysine and arginine residues were found 
to be targeted for methylation. The methylation hot spots include lysines 4, 9, 
27 and 36 of H3, lysine 20 of H4, arginines 2, 17, and 26 of H3, and arginine 3 
of H4. Since the stable cell line SNU-398 with constitutive expression of 
METTL7A for the original purpose of functional studies has been established, 
we took advantage of this stable cell line and checked if there was any change 
in the methylation status of H3K4, K9, K27 and K36 by immunoblotting. 
Unfortunately, we did not discover any significant change in the trimethylation 
status of the aforementioned H3 lysine residues (Figure 6-18A). Protein 
specific methylation study, e.g. histone, was limited by the antibodies available 
in the laboratory, therefore a general methylation profile for the whole proteome 
should be generated with anti-pan methyl lysine or arginine antibodies. 
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Interestingly, with anti-methylated lysine antibody which was generated against 
mono-methyl and di-methyl lysines, we identified a unique protein band in the 
total cell lysate of SNU-398 cells with constitutive METTL7A expression 
(Figure 6-18B). Therefore, we proposed that METTL7A might catalyse lysine 
methylation on some unknown target proteins, more probably monomethylation 
or dimethylation. In future, it would be interesting to identify the methylation 
substrates of METTL7A and their methylation status by mass spectrometry. 
 
Figure 6-18 Potential protein methylation activity test for METTL7A. (A) 
Immunoblots of the indicated proteins to detect the methylation status of 
different histone 3 lysine residues of SNU-398 cells with constitutive expression 
of METTL7A. H3, histone 3; K, lysine residue; Me3, trimethylation; EV, empty 
vector. (B) Left: Immunoblot of the total cell lysate of the indicated stable SNU-
398 cells using anti-pan methyl lysine antibody. Right: Ponceau S staining of 





To further confirm that METTL7A indeed can function as a protein 
methyltransferase, we planned to perform in vitro methylation assays with the 
purified GST-tagged METTL7A and various histone substrates incubated in the 
presence of S-adenosyl-L-[methyl-3H]-methionine (Fingerman et al., 2008). 
Expression of GST-tagged METTL7A in the chemically competent E. coli 
BL21 was induced by isopropyl β-D-1-thiogalactopyranoside (IPTG). The 
optimal GST-METTL7A induction condition was determined by testing 
different concentrations of IPTG at different temperatures for various induction 
durations (Figure 6-19 and Figure 6-20A). GST-tagged METTL7A is 
predicted to have a molecular weight of 54 kDa. Among all the conditions tested, 
induction with 40 μM of IPTG at 26⁰C for overnight was most efficient to 
induce GST-METTL7A expression. However currently we have not been able 
to purify a significant amount of GST-METTL7A for the subsequent in vitro 
methylation assays (Figure 6-20B), because most of the GST-METTL7A 
protein was lost to the flow-through of the bacteria lysate after passing through 
the glutathione beads (Figure 6-20C). For future study, the protein purification 
procedure can be optimized by increasing the incubation time of the bacteria 
lysate with the glutathione beads; otherwise the recombinant METTL7A protein 







Figure 6-19 Induction of GST-tagged METTL7A expression by isopropyl 
β-D-1-thiogalactopyranoside (IPTG). Expression of GST-METTL7A in E. 
coli BL21 was induced by the indicated concentrations of IPTG at different 
temperatures and for different durations. Picture shown is the coomassie blue 
staining of BL21 lysate resolved by SDS-PAGE. The GST-METTL7A was 
predicted to have a molecular weight around 54 kDa, indicated by the arrow.  
 
Figure 6-20 Purification of GST-tagged METTL7A from BL21 E. coli. (A) 
Induction of GST-tagged METTL7A expression by 40 µM of IPTG for 
overnight at 26ºC. Total lysate of BL21 E. coli was resolved by SDS-PAGE and 
stained with coomassie blue. (B) Purified GST and GST-METTL7A resolved 
by SDS-PAGE, and stained with coomassie blue. (C) The flow-through of BL21 
E. coli lysate after passing through the glutathione beads analysed by SDS-
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In addition to functioning as a potential protein methyltransferase, 
METTL7A might be able to catalyse DNA methylation, too. DNA methylation 
occurs to the C5 position of cytosine, converting the cytosine to 5-
methylcytosine. Cytosine methylation usually occurs in the CpG dinucleotide 
context, and plays an important role in regulating gene expression (Robertson, 
2005). For a preliminary test, methylation-sensitive restriction enzyme 
digestion followed by gene specific PCR (MSRE-PCR) was used to study gene 
specific DNA methylation status (Melnikov et al., 2005). The principle of 
MSRE-PCR is illustrated in Figure 6-21. Briefly, in the absence of DNA 
methylation, target DNA will be cleaved by the restriction enzymes, rendering 
no template for PCR amplification by primers flanking the methylation site. In 
contrast, in the presence of DNA methylation, methylated DNA is protected 
from the restriction enzyme digestion, and can serve as a template for the 
successful PCR amplification. To test our hypothesis that METTL7A can 
function as a DNA methylation enzyme, gDNA of SNU-398 cells with 
constitutive METTL7A expression was digested with methylation sensitive 
restriction enzyme SmaI. The undigested gDNA and XmaI (methylation 
insensitive enzyme) digested gDNA served as controls. Primers targeting 
SALL4 intron 1 CpG island containing 4 SmaI/XmaI sites were used for the 
gene specific PCR (Figure 6-22A). MSRE-PCR of SALL4 intron 1 indicated 
no enhanced methylation of this region in SNU-398 cells with constitutive 
METTL7A expression (Figure 6-22B). However, this single gene specific 
MSRE-PCR did not exclude the possible DNA methylation activity associated 
with METTL7A. For future study, gene expression profiling of SNU-398 cells 
with constitutive METTL7A expression will provide critical information to 
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select the candidate target regions for MSRE-PCR. This is because DNA 
methylation is usually associated with gene expression depression, therefore 
genes showing decreased expression upon METTL7A overexpression might 
be interesting targets for MSRE-PCR.  
 
Figure 6-21 Principle of MSRE-PCR to detect the methylation status at 
specific CpG sites. Left: in the absence of methylation at a particular CpG site, 
DNA can be digested by the restriction enzyme, resulting in no PCR 
amplification with primers flanking the restriction enzyme recognition site. 
Right: in the presence of methylation, DNA is protected from the restriction 
enzyme digestion, and serves a template for the successful PCR amplification. 






Figure 6-22 MSRE-PCR of SALL4 intron 1 CpG island with gDNA from 
stable SNU-398 cells. (A) Schematic diagram of PCR amplicon targeting 
SALL4 intron 1 CpG island. This region spans around 1.5 Kb, and contains 4 
SmaI/XmaI recognition sites. (B) MSRE-PCR of SALL4 intron 1 CpG island 
with the indicated gDNA templates. EV, empty vector.  
1.5 Kb
SALL4 Intron 1
1 2 3 4 5 6 1. SNU398 EV gDNA 
2. SNU398 EV gDNA SmaI 
3. SNU398 EV gDNA XmaI 
4. SNU398 METTL7A gDNA 
5. SNU398 METTL7A gDNA SmaI 

















6.5  RNA editing of METTL7A 3’UTR in primary HCC 
patient samples 
ADAR1 and ADAR2 were shown to be differentially expressed in HCC, 
leading to the distinct editing profiles of different target genes (Chan et al., 
2013). In this study, METTL7A has been demonstrated to be edited by both 
ADAR1 and ADAR2 in its 3’UTR, it is interesting to study if the editing of 
METTL7A 3’UTR displays a general trend in primary HCC patient samples.  
METTL7A 3’UTR has been shown to be an common editing target of 
ADAR1 and ADAR2 through the co-transfection experiment in both HEK-293 
cells and SNU-398 cells, and its editing frequency displayed a significant 
correlation with ADARs expression in both cell lines (Figure 5-3). In primary 
HCC patient samples, it is also interesting to investigate if a similar correlation 
between ADARs expression level and METTL7A 3’UTR editing frequency can 
be observed. Hence METTL7A 3’UTR editing frequency of 113 pairs of primary 
HCC tumor and the matched adjacent non-tumorous samples was measured by 
Sanger sequencing. There are multiple editing sites in METTL7A 3’UTR. 
Therefore, to study the correlation between ADARs expression and METTL7A 
3’UTR editing in HCC, we made use of the average editing frequency of 
METTL7A 3’UTR. The average METTL7A 3’UTR editing frequency for each 
patient was calculated from the 10 representative editing sites selected before 
(Figure 4-10A). Compared to the cell line experiment, changes of METTL7A 
3’UTR editing in HCC tumors compared to the matched adjacent non-tumorous 
tissues correlated significantly only with ADAR1 expression changes, but not 
with ADAR2 expression changes (Figure 6-23). Therefore, in primary HCC 
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patient samples, ADAR1 might be the sole enzyme catalysing METTL7A 
3’UTR editing.  






20 P < 0.0001
R2 = 0.41
































Figure 6-23 Correlation of METTL7A 3’UTR editing with ADARs 
expression in primary HCC samples. The average METTL7A 3’UTR editing 
frequency for each patient was calculated from the 10 representative editing 
sites selected before (Figure 4-11A). Changes of the average METTL7A 3’UTR 
editing were derived as the editing frequencies in HCC tumor samples relative 
to the editing frequencies in the matched adjacent non-tumorous samples, 
similarly for ADAR1 and ADAR2 expression changes. Dot plot showed the 
correlation of changes in METTL7A 3’UTR editing with ADAR1 expression 
changes (left panel) and ADAR2 expression changes (right panel). 
  
ADAR1 expression has been shown to be significantly upregulated in 
HCC (Chan et al., 2013). Given the significant correlation between METTL7A 
3’UTR editing and ADAR1 expression in HCC, we next studied if there was 
any significant difference in METTL7A 3’UTR editing between HCC tumors 
and the matched adjacent non-tumorous tissues. The editing frequency for each 
of the 10 representative editing sites in METTL7A 3’UTR was measured by 
Sanger sequencing, but demonstrated no significant difference between HCC 
tumors and the matched adjacent non-tumorous tissues, except site 4 (Figure 
6-24). Similarly, the average METTL7A 3’UTR editing frequency showed no 
significant difference between HCC tumors and the matched adjacent non-
tumorous tissues, either (Figure 6-25). The lack of difference in METTL7A 
3’UTR editing between HCC tumors and the matched adjacent non-tumorous 
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tissues might be due to the opposite expression changes of ADAR1 and ADAR2 
in HCC tumors. The effects of increased ADAR1 expression on METTL7A 






Figure 6-24 Editing frequencies of the 10 representative editing sites of METTL7A 3’UTR in HCC. Dot plot showing the 
editing frequency for each individual editing site of METTL7A 3’UTR in HCC tumors and the matched adjacent non-tumorous 
tissues. Values indicating the position of the editing site referring to Figure 4-11A. N, matched non-tumorous tissues; T, HCC 
tumors. 
 







































Figure 6-25 The average METTL7A 3’UTR editing in primary HCC 
tumors and the matched adjacent normal tissues. The average METTL7A 
3’UTR editing frequency was measured for 113 pairs of HCC tumors and the 
matched adjacent normal tissues, and calculated from the 10 representative 



































 ALTERNATIVE HYPOTHESES 
DURING THE EXPLORATIVE PHASE OF THIS 
STUDY 
7.1 Alteration of miRNA targeting to the edited 3’UTRs 
ADARs have been shown to be differentially expressed in HCC, and 
contribute to HCC development at least in part through the altered recoding 
editing of certain target genes, e.g. AZIN1 (Chen et al., 2013). However our 
study together with previous reports have revealed that A-to-I RNA editing is 
significantly enriched in 3’UTRs, and the involvement of ADARs in HCC 
development through 3’UTRs editing remains to be studied. 3’UTRs editing has 
been demonstrated to regulate the target transcript stability by altering the 
miRNA targeting of certain genes (Borchert et al., 2009; Wang et al., 2013). At 
the beginning of our study, we also aimed to identify candidate genes with 
3’UTRs editing which can potentially alter the miRNA targeting. 
Candidate genes were selected from the intersection list of the RNA-seq 
data generated from the three pairs of primary HCC tumor and the matched 
adjacent normal tissues (Figure 4-5). The genetic structures of selected 
candidate genes were illustrated in Figure 7-1. To test the potential of 3’UTRs 
editing in affecting the transcript stability through miRNA retargeting, only a 
fragment of the edited 3’UTRs for each gene were cloned into the pmirGLO 
dual-luciferase expression vector. cDNA from the primary HCC tumor sample 
(patient ID: 473) was used as the template for cloning, and different clones were 
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selected for the luciferase assay in order to include different editing patterns for 
the same 3’UTRs. The editing patterns for different clones of one example gene 
TNFAIP8L1 were illustrated in Figure 7-2. The luciferase assays of different 
genes revealed no much difference in the luciferase activities among different 
pmirGLO clones, except CTSB (Figure 7-3). The difference in the luciferase 
activities between different pmirGLO-CTSB-3’UTRs clones might be due to the 
change of miRNA targeting. To identify the miRNAs which potentially caused 
the different luciferase activities observed between different CTSB clones, 
miRNAs targeting both the edited region 1 and region 2 of CTSB 3’UTR were 
predicted by miRWalk and miRBase (Table 7-1). In future, it will be important 
to validate the predicted miRNAs to target CTSB 3’UTR by luciferase assays. 
 
Figure 7-1 The genetic structures of selected candidate genes. The black 
boxes represent the coding regions, and the lines stand for the untranslated 
regions (UTRs). The strokes in the 3’UTRs mark the primer positions to clone 
the corresponding fragments into pmirGLO dual-luciferase expression vector. 




















Figure 7-2 The editing patterns for different clones of pmirGLO-
TNFAIP8L1 3’UTR. The fragment of TNFAIP8L1 3’UTR cloned into 
pmirGLO dual-luciferase expression vector contains 13 editing sites illustrated 
in this figure as the circles. Filled circles represent the edited sites, and open 
circles represent the non-edited sites. Clone numbers were indicated on the right 
side of the figure. Different clones carry different combinations of A-to-G and 
T-to-C mutations. A-to-G mutations indicate the editing of positive strand, 
while T-to-C mutations indicate the editing of negative strand. 
T T T T 















Figure 7-3 Luciferase assays of different pmirGLO-3’UTR clones for 
different genes. Different clones of pmirGLO-3’UTRs of different genes were 
used for transfection in HEK-293 cells. 24 hours post transfection, luciferase 
activity was measured. MTDH1 and MTDH2 indicate the two different 
fragments cloned for MTDH 3’UTR, similarly for CTSB1 and CTSB2 (Figure 
7-1). n = 3, * P < 0.05, ** P < 0.01, *** P < 0.001. 
 
Table 7-1 miRNAs predicted to target CTSB 3'UTR region 1 (CTSB1) 








































































































































































































































































































































































































































































7.2 Editing dependent regulations of ADARs on METTL7A 
Until the generation of different ADARs mutants, we hypothesized that 
ADARs regulate METTL7A expression through direct 3’UTR editing. 
Extensive 3’UTRs editing was reported to cause nuclear retention of the target 
mRNA due to the specific interaction between P54nrb complex with inosines 
(Zhang & Carmichael, 2001). Therefore to study if ADARs suppress 
METTL7A expression through a similar mechanism, the subcellular 
localization of METTL7A mRNA upon ADARs expression modulation was 
investigated. Indeed, nuclear fractionation of SMMC-7721 cells with 
constitutive ADARs expression demonstrated that nuclear retention of 
METTL7A mRNA was enhanced with ADARs overexpression (Figure 7-4). 
Moreover, P54nrb RIP followed by RT-PCR in HEK-293 cells demonstrated that 
more METTL7A mRNA was pulled down by anti-P54nrb antibody with the 
overexpression of ADARs (Figure 7-5). The increased interaction between 
P54nrb and METTL7A mRNA with the overexpression of ADARs might explain 
the increased nuclear retention of METTL7A mRNA, because P54nrb is 
multifunctional nuclear protein. In addition to that, P54nrb is also an inosine 
specific protein, and the inosine specificity associated with P54nrb indicates that 







Figure 7-4 Nuclear fractionation of SMMC-7721 cells with constitutive 
ADARs expression. SMMC-7721 cells with stable expression of ADAR1 and 
ADAR2 were nuclear fractionated for RNA extraction. (A) qPCR of METTL7A 
showing the increased nuclear retention of METTL7A mRNA in SMMC-7721 
cells with overexpression of ADARs. (B) 1% agarose gel analysis of the total 
RNA extracted from the cytoplasmic and nuclear lysate of the indicated 
SMMC-7721 stable cells. The two prominent bands in the picture indicate the 
28s rRNA and 18s rRNA. The absence of rRNA in the nuclear lysate indicates 
the successful nuclear fractionation. N, nuclear; C, cytoplasmic.  
 
 
Figure 7-5 RNA immunoprecipitation (RIP) of P54nrb in HEK-293 cells 
with ADARs overexpression. (A) Immunoblots of the indicated proteins of 
HEK-293 cells 48 hours after transfection with either the empty vector (EV) or 
ADARs overexpressing constructs. (B) Immunoblot showing the successful 
immunoprecipitation of P54nrb in HEK-293 cells with ADARs overexpression. 
(C) RT-PCR of the indicated genes with cDNA generated from the RNA 
immunoprecipitated by anti-P54nrb antibody in HEK-293 cells. P54nrb RIP was 
performed with HEK-293 cells transfected with ADARs overexpressing 
constructs. (D) qPCR of METTL7A mRNA that was pulled down by anti-P54nrb 
antibody in HEK-293 cells with overexpression of ADARs.  






































7.3 Additional candidate genes 
Along our study, we continued to validate the 3’UTRs editing of more 
genes, hoping to find some functionally important genes displaying specific 
changes in their 3’UTRs editing during HCC development. RBBP9 
(retinoblastoma-binding protein 9) is one of the genes that we have validated 
carrying 3’UTR editing. RBBP9 was initially discovered as Bog (B5T over-
expressed gene), and was demonstrated to be overexpressed in primary HCC 
tumors (Woitach et al., 1998). Furthermore, RBBP9 was shown to be important 
to transform the rat liver epithelial (RLE) cells into cancerous cells through the 
interaction with retinoblastoma protein and the subsequent displacement of 
E2F-1 from the retinoblastoma protein (Woitach et al., 1998). In addition to its 
retinoblastoma-binding function, RBBP9 was also reported to be a serine 
hydrolase involved in pancreatic cancer development by subverting the anti-
proliferative function of TGF-β (Shields et al., 2010). 
In our preliminary study of RBBP9 in HCC, RBBP9 was validated to 
carry 3’UTR RNA editing by Sanger sequencing, and its 3’UTR was predicted 
to form an extensive dsRNA structure spanning around 300 bp (Figure 7-6). 
More importantly, the editing frequencies of the 6 editing sites of RBBP9 
3’UTR was measured by Sanger sequencing for 4 pairs of HCC tumors and the 
matched adjacent normal tissues (Figure 7-7). Interestingly, from this limited 
number of primary HCC patient samples, a general reduction of RBBP9 3’UTR 
editing was observed. In future, it will be important to validate this observation 
with a larger cohort of patient samples, and to study if the reduced RBBP9 
3’UTR editing contributes to HCC development. For future functional study of 
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RBBP9 in the appropriate cell model, RBBP9 mRNA expression was screened 
for a series of HCC cell lines (Figure 7-8). 
 
Figure 7-6 RNA secondary structure prediction for RBBP9 3’UTR. The 
first Alu element (on the positive strand) and the second Alu element (on the 
negative strand) of RBBP9 3’UTR were predicted to form an extensive dsRNA 
secondary structure by CentroidFold. Shown is the heat color gradation from 
blue to red indicating the base-pairing possibility from 0 to 1.  
 
 
Site 1 chr20:18,468,413 
Site 2 chr20:18,468,379 
Site 3 chr20:18,468,361 
Site 4 chr20:18,468,351 
Site 5 chr20:18,468,352 
Site 6 chr20:18,468,339 
 
Figure 7-7 Editing frequencies of RBBP9 3’UTR in primary HCC patient 
samples. (A) Pie charts showing the editing frequencies for each of the 
indicated RBBP9 3’UTR editing sites. Results from 4 pairs of primary HCC 
tumors and the matched adjacent normal tissues were presented. The greyer area 
of each pie chart represents the editing frequency of each site. (B) The 
chromosome coordinate of each editing site in NCBI Build 37.1/hg19. (C) PCR 
amplicon sequence covering the 6 editing sites listed in the table. Yellow 
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Figure 7-8 RBBP9 mRNA expression in different HCC cell lines. qPCR of 
RBBP9 with the cDNAs of indicated HCC cell lines. cDNA was prepared with 























8.1 Extensive 3’UTR editing as a footprint of ADARs binding 
Extensive A-to-I editing in 3’UTRs has been reported to lead to different 
fates of edited mRNAs, including changes in the transcript stability and 
subcellular localization. RNA editing in 3’UTRs can regulate the transcript 
stability by creating or eliminating miRNA targeting sites due to the difference 
in base pairing property between adenosine and inosine (Borchert et al., 2009; 
Wang et al., 2013). Alternatively, promiscuous 3’UTRs editing can recruit 
inosine-specific nucleases, e.g. the RISC subunit Tudor-SN and human 
endonuclease V, leading to target mRNA degradation (Morita et al., 2013; 
Scadden, 2005). Furthermore, extensive 3’UTRs editing can also affect the 
subcellular localizations of edited mRNAs; certain edited dsRNA were shown 
to be retained in the nucleus by an inosine-specific nuclear protein complex. 
This complex was shown to contain P54nrb, splicing factor PSF, and inner 
nuclear matrix structural protein matrin 3 (Nishikura, 2010; Prasanth et al., 
2005).  
All of the above reported fates of inosine containing RNAs emphasized 
the importance of inosine in either changing the base-pairing properties or 
recruiting inosine-specific protein complexes, thereby affecting the 
translatability of the edited mRNA. In our study we also observed the 
interaction between P54nrb and METTL7A mRNA by RIP, and the interaction 
between them increased with overexpression of ADARs in HEK-293 cells 
(Figure 7-5). This suggests the direct involvement of 3’UTRs RNA editing in 
regulating METTL7A expression. However, with the generation of different 
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ADAR mutants including the DeAminase Domain mutants (DeAD mutants) 
and the DRBD mutants (EAA mutants), METTL7A expression was found to 
be suppressed by all forms of ADARs including the wild types and the mutants. 
This indicates that editing activities of ADARs play no role in the suppression 
of METTL7A expression. Indeed, a previous study in C. elegans also observed 
no significant difference in the expression of mRNAs with structured and 
edited 3’UTRs across different adr strains (Hundley et al., 2008). Furthermore, 
mRNAs with edited 3’UTRs have been demonstrated to associate with 
translating polyribosomes in both C. elegans and human HeLa cells (Hundley 
et al., 2008). In combination with our finding that ADARs suppressed 
METTL7A expression independent of their editing activities (shown by the 
DeAD and EAA mutants), we suggest that the extensive 3’UTRs editing for 
certain mRNAs (e.g. METTL7A) could be merely an indicator of physical 
interaction between ADARs and the structured 3’UTRs. 3’UTR editing does 
not necessarily indicate a direct regulation of ADARs to the target genes 
through editing. ADARs could regulate gene expression through an editing 
independent mechanism. 
8.2 Editing independent functions of ADARs 
Editing independent functions of ADARs have always been intriguing 
since too few editing produced protein variants have been discovered to 
account for the biological phenotypes observed in the animal models with 
genetically modified ADARs (Nie et al., 2005). Even though the ectopic 
expression of the edited GluR-B could rescue the lethality of Adar2 null mice 
(Higuchi et al., 2000), an indistinguishable phenotype of hyperphagia-mediated 
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obesity was later observed in both the wild-type and the deaminase-deficient 
Adar2 transgenic mice by Singh et al. (Singh et al., 2007). These reports 
suggest there are still editing independent activities associated with Adar2. On 
the other hand, editing independent functions associated with ADAR1 were 
discovered unexpectedly in search for ADAR1 interaction proteins in vivo. 
ADAR1 was found to interact with the nuclear factor 90 (NF90) family of 
proteins including NF45, NF90 and NF110 via the DRBD, and the interaction 
was found to be bridged by dsRNA (Nie et al., 2005). Moreover, they also 
identified that ADAR1 can promote NF90-mediated gene expression 
independent of its editing activity, given the similar phenotype observed for 
both the wild type and the deaminase domain truncated ADAR1 (Nie et al., 
2005). In contrast to the truncated ADARs proteins used in the previous studies, 
the ADARs EAA mutants used in our study bear minimal structural changes to 
ADARs by endowing point mutations to DRBDs. Therefore, not only the 
editing independent functions, but also the dsRNA binding independent 
functions of ADARs could be well addressed in this way. Here, we highlighted 
a novel link between ADARs and miRNA expression independent of their 
editing and dsRNA binding activities. We identified that ADARs can form a 
complex with Dicer to promote miRNA processing, thereby regulating the 
expression of a wide array of genes independent of their editing activities. 
ADAR1 has been demonstrated to interact with Dicer to promote miRNA 
processing(Ota et al., 2013). Here we showed that not only ADAR1 but also 
ADAR2 can interact with Dicer to promote miRNA processing.  
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8.3 Interaction of ADARs and RNAi pathway 
Given the shared dsRNAs substrate, interactions between ADARs and 
the RNAi pathway have gained intensive attentions during the past decade 
(Nishikura, 2006). The competition of ADARs for the shared dsRNAs to 
prevent them from entering the RNAi pathway was first speculated by Bass 
(Bass, 2000). However with recent studies, both antagonistic and agonistic 
effects of ADARs on RNAi pathway have been described.  
The inhibitory effects of dsRNA hyper-editing on RNAi processing were 
first confirmed by in vitro biochemical assays. dsRNAs that are edited to have 
50% of A-to-I conversion in vitro by the recombinant ADARs proteins were 
shown completely incompetent for RNAi mediated gene silencing, which was 
proven to be caused by the reduced production of short interfering RNA 
(siRNA) (Scadden & Smith, 2001b). The protection of structured dsRNAs 
from entering RNAi pathway by A-to-I editing was further confirmed by in 
vivo studies in C. elegans. Deletion of adr-1 and adr-2 in C. elegans resulted 
in defective chemotaxis (Tonkin et al., 2002); however the defects could be 
rescued by the deletion of genes critical for RNAi response rde-1 and rde-4 
genes (Tonkin & Bass, 2003). This strongly argues that genes involved in 
normal chemotaxis are subjected to enhanced RNAi response in adr null 
worms, and underlines the physiological importance of A-to-I editing in 
prevention of the dsRNAs from siRNA synthesis. In addition to the inhibition 
of siRNA processing from a long dsRNA substrate by A-to-I editing as 
described above, ADARs can also act as direct siRNA binding proteins to 
inhibit its efficacy in gene silencing. ADARs were shown to bind to siRNA 
without RNA editing through the DRBDs, and the siRNA silencing effects 
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were significantly enhanced in ADARs null mouse embryonic fibroblasts (Yang 
et al., 2005). The negative effects of ADARs on RNAi pathway suggest that 
ADARs can function as negative feedback regulators in RNAi response. Indeed, 
high doses of siRNA injection into mice have been shown to induce the 
expression of Adar1 which in turn suppresses the siRNA silencing efficacy 
(Hong et al., 2005). 
With more recent findings of miRNAs which also involve dsRNA 
formation during their biosynthesis, editing has been suggested to occur to at 
least 6% of pri-miRNAs by a systemic survey across 10 human tissues (Blow 
et al., 2006). A recent larger scale survey in human brain tissue indicated that 
around 16% of pri-miRNAs were subjected to A-to-I editing (Kawahara et al., 
2008). Given the structural and sequence alterations implicated, A-to-I editing 
can have broad implications in miRNA processing, production and target 
silencing. For example, editing of pri-miR-142 was shown to suppress Drosha 
cleavage and lead to subsequent Tudor-SN mediated degradation (Yang et al., 
2006). Inhibition of Dicer-TRBP cleavage of pre-miRNAs by RNA editing was 
also demonstrated for pri-miR-151 (Kawahara et al., 2007). Even though A-to-
I editing of pri-miRNAs can lead to structural changes and subsequently 
inefficient processing, some of the A-to-I editing sites can be structurally 
tolerated and eventually incorporated into the mature miRNAs. Editing sites 
incorporated into the mature miRNAs, especially those located in the seed 
sequences, can potentially redirect miRNAs silencing targets, as shown for 
miR-376 (Kawahara et al., 2007). In addition to the editing dependent 
antagonistic effects of ADARs on the miRNA pathway, editing independent 
inhibition of ADARs on miRNA processing was also reported for both ADAR1 
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and ADAR2. For example, Drosha cleavage of pri-miR-376a2 can be inhibited 
by both the wild type and deaminase inactive ADAR2 in vitro (Heale et al., 
2009). 
All of those above described studies have focused on the competition 
between ADARs and the RNAi or miRNA pathway. However, a recent study 
about the interactions between ADAR1 and RISC component proteins revealed 
some agonistic effects of ADAR1 on miRNA processing, by forming a 
complex with Dicer (Ota et al., 2013). ADAR1-Dicer complex not only 
promotes the cleavage of pre-miRNA, but also facilitates the loading of 
miRNA to the RISC complex (Ota et al., 2013). Here, we observed that both 
ADAR1 and ADAR2 (wild-type and EAA mutants) augmented miR-27a 
expression, therefore demonstrating that both ADAR1 and ADAR2 have the 
editing independent promoting effects on miRNA processing. Moreover, we 
also showed that both ADAR1 and ADAR2 can interact with Dicer to promote 
the global miRNA processing. Given the potentially widespread gene 
expression regulations of ADARs through miRNAs, the interaction between 
ADARs and Dicer could be a therapeutic target for HCC treatment.  
8.4 ADARs and HCC development 
Previous studies of ADARs in HCC have mainly focused on their 
recoding abilities, and attempted to identify the downstream recoded proteins 
with altered functions. For example, AZIN1 was found hyper-edited by 
ADAR1 in HCC tumors, resulting in a gain-of-function mutation and enhanced 
tumorigenicity of the edited AZIN1 (Chen et al., 2013). Large scale RNA-seq 
studies also revealed a picture of imbalanced editome in HCC, characterized 
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by the hyper-editing of FLNB and hypo-editing of COPA.(Chan et al., 2013) 
However the contributions of edited FLNB or COPA to HCC development have 
not yet been demonstrated. In this study, METTL7A was shown to behave as 
a novel tumor suppressor in HCC by various in vitro and in vivo assays. More 
importantly, we also identified the reduced METTL7A expression in primary 
HCC patient samples, and the reduced METTL7A expression predicts poorer 
overall survival of HCC patients. However METTL7A expression was found 
to be regulated by ADARs independent of their editing activities through 
miRNA modulation. Therefore here we discovered an editing independent 
mechanism of ADARs in contribution to HCC development. miR-27a is just 
one of the many miRNAs regulated by ADARs independent of their editing 
activities. Given the multiple targeting effects of miRNAs, dysregulation of 
ADARs expression in HCC might induce dysregulation of many genes. Editing 
independent contributions of ADARs to HCC development can potentially be 
dissected with different ADARs mutants generated in this study. 
8.5 METTL7A and HCC development 
In our study, METTL7A was found to be significantly down regulated in 
HCC, and the loss of METTL7A expression in HCC predicted poorer overall 
survival and disease-free survival of HCC patients. These strongly suggest that 
METTL7A functions as a novel tumor suppressor in HCC. The tumor 
suppressive functions of METTL7A were further confirmed by a variety of in 
vitro and in vivo assays. However the detailed mechanisms by which METT7A 
suppresses the tumor development await further investigation, especially 
whether METTL7A possesses any intrinsic enzymatic activities.  
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METTL7A is predicted to be a SAM-dependent methyltransferase based 
on the sequence homology. SAM-dependent methyltransferase is a diverse 
family of transmethylation enzymes which can catalyse methylation on a wide 
range of substrates, e.g. lipids, nucleic acids, and proteins etc. Our preliminary 
experiment with anti-methylated lysine antibody suggested that METTL7A 
can be a potential protein lysine methyltransferase (PKMT). However the 
substrate specificity of METTL7A still needs further investigation. In vitro 
methylation assay with the recombinant histone peptide followed by mass 
spectrometry might provide further insights regarding to the detailed 
methylation status of the substrate.  
The close phylogenetic distance of METTL7A to a known RNA 
methyltransferase ALKBH8 suggests that RNA might be another class of 
methylation substrates for METTL7A. ALKBH8 was demonstrated to interact 
specifically with certain tRNAs with wobble uridines, specifically with 
tRNAArg(UCU) and tRNAGlu(UUC). It is required for methylation of the wobble 
uridines to generate 5-methylcarboxymethyl uridine (mcm5U) (Fu et al., 2010). 
mcm5U is an important anticodon loop modification involved in DNA damage 
survival. Cells depleted of ALKBH8 were shown to be sensitive to the 
treatment of alkylating agent methanesulfonate which can induce DNA 
damages (Fu et al., 2010). Given that METTL7A is clustered to the same 
phylogenetic branch as ALKHB8 (Figure 6-3), it will be very interesting to 
investigate if METTL7A can catalyse similar tRNA modifications in future. 
Apart from proteins and nucleic acids, lipids might also serve as potential 
methylation substrates for METTL7A since METTL7A was initially 
discovered as a lipid droplet associated protein (Zehmer et al., 2008b). 
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 CONCLUSIONS AND FUTURE 
PERSPECTIVES 
9.1 Conclusions 
In conclusion, we here revealed a novel editing independent mechanism 
of ADARs in contribution to HCC development. ADARs were shown to 
interact with Dicer to promote the miRNA processing. Importantly, METTL7A 
is probably just one of the many downstream genes regulated by ADARs in an 
editing independent manner through miRNA expression modulation. The 
interaction between ADARs and Dicer identified in this study will be of great 
significance for understanding cancer development as well as for the 
development of novel therapeutic approaches. 
9.2 Future perspectives 
9.2.1 ADAR and miRNA interaction 
We have revealed the novel interaction between ADARs and miRNA 
processing through a gene specific study, and the global miRNA expression 
changes upon ADARs overexpression were also profiled using a microarray 
system. However we failed to validate some of the microarray data. In future, 
small RNA-seq can be applied to generate more confident data for the global 
miRNA expression profiling. Moreover, mapping the interaction domains 
between ADARs and Dicer will support future drug development to target 
ADARs editing independent functions.  
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9.2.2 Significance of editing in the non-coding regions 
Even though in this study we have demonstrated an editing independent 
regulation mechanism of genes with extensive 3’UTR A-to-I editing by 
ADARs, it does not exclude the possibility that ADARs editing activities are 
important for regulating the non-coding regions. Previous studies have 
revealed the different consequences of extensive editing in the non-coding 
regions; however there are conflicting observations scattered around. Therefore 
further efforts should be devoted to study the editing in the non-coding regions. 
9.2.3 Editing site selectivity 
The puzzling difference in the editing site preference between coding and 
non-coding regions still awaits to be solved. Certain editing sites can be very 
selective (Glu-R Q/R site) (Sommer et al., 1991), however others can be very 
promiscuous (the non-coding regions). Current hypothesis implies that the 
substrate dsRNA structure plays a critical role in determining the editing site. 
However we can probably only identify the underlying mechanism of editing 
site selection until the structure of the intact ADARs proteins bound to the 
dsRNA substrate is solved.  
9.2.4 Regulators of ADARs enzymatic activities 
Most studies regarding to the regulation of ADARs activities have 
focused on studying the ADARs expression changes, especially the studies in 
cancer development. However ADARs, similar to other proteins, are subjected 
to multiple levels of regulation, e.g. self-editing of ADAR2 and the subcellular 
localizations (Fritz et al., 2009; Rueter et al., 1999). Other regulatory factors, 
e.g. the interaction partners and post-translational modifications are still calling 
for attentions.  
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9.2.5 The underlying mechanisms for the lethality of Adar1 -/- mouse 
embryos 
In contrast to the rescue of Adar2 -/- mouse seizure prone phenotype by 
the ectopic expression GluR-B R form (Higuchi et al., 2000), the critical editing 
substrate of Adar1 is still waiting to be identified to explain the lethality 
observed in Adar1 -/- mouse embryos. However a recent study suggests that 
the editing independent effects of ADAR1 on miRNA biosynthesis are critical 
during mouse embryonic development (Ota et al., 2013). This hypothesis still 
needs further evidences, e.g. the mouse rescue model, to support itself. 
9.2.6 Physiological importance of A-to-I RNA editing 
Similar to alternative splicing, A-to-I RNA editing generates extensive 
transcriptomic diversities. However instead of conferring the protein 
information by RNA editing, why do not the organisms just encode the 
information in the genomic DNA? Other than the flexibility of RNA editing 
compared to the hardwired DNA coding, are there other physiologically 
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